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High Rates of Undiagnosed Pulmonary Tuberculosis and Barriers to Diagnosis and 
Care Among HIV-positive Patients in a Rural South African Hospital: A Cross-
sectional cohort study 
 
Palav A. Babaria, N. Sarita Shah, Anthony P. Moll, Neel R. Gandhi, Gerald H. Friedland. 
Yale AIDS Program, Department of Internal Medicine, Yale University School of 
Medicine, New Haven, CT. 
 
 Tuberculosis (TB) is the leading cause of mortality among HIV infected 
patients in South Africa. Symptoms of active TB may be subtle in HIV patients and go 
unrecognized in early illness, creating an opportunity for nosocomial TB transmission. 
Late presentation and delayed diagnosis of TB also contribute to increased mortality and 
community-based TB transmission. In an effort to identify active TB promptly, screening 
for TB must be integrated into routine HIV care and barriers to seeking care must be 
addressed. 
 We prospectively initiated a standardized TB screening program at a rural 
HIV clinic to determine the prevalence of unsuspected TB and drug-resistant TB. All 
HIV clinic patients at a rural hospital in Tugela Ferry, South Africa were screened for TB 
symptom and those with one or more TB symptoms (e.g., cough, night sweats, fever) 
were enrolled and submitted sputum samples for microscopy, mycobacterial culture and 
drug-susceptibility testing (DST). We also administered a questionnaire to all inpatient 
and outpatient participants based on the Information, Motivation, and Behavioral Skills 
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(IMB) model in order to identify barriers to TB diagnosis and care. 
Among 263 HIV-infected ambulatory patients enrolled, 52 (20%) were culture-
positive for TB and 24 (9%) were smear-positive. Among 46 patients with available DST 
results, 13 (5% of 263 screened) were resistant to at least isoniazid and rifampin (MDR 
TB); and 7 of these (3%) met criteria for XDR TB. Patients with TB were more likely to 
be male (p=.01), without a prior history of TB (p=.02), and had lower median CD4 
counts (p<0.001). Patients presented with similar symptoms irrespective of TB status, 
except for weight loss, which was significantly greater among those with TB. Twenty 
seven percent of all patients reported delaying seeking care for >4 weeks. Delay was 
associated with male gender (p=0.02), not on ARVs (p<0.001), and being seen elsewhere 
for treatment (p=0.003). Among 480 patients who completed the IMB questionnaire, 387 
(81%) thought TB was treatable and 231 (48%) thought that having TB meant you also 
had HIV. Almost all felt that they could disclose their TB (97%) or HIV (88%) status to a 
family member. However, several barriers to seeking care were identified: 294 (61%) 
stated they lived too far to be treated and 263 (55%) lacked finances for transport to the 
hospital. 
This study demonstrates a high prevalence of active TB, particularly MDR & 
XDR TB, among HIV clinic patients in rural South Africa. These unrecognized TB cases 
raise concern for nosocomial TB transmission among vulnerable HIV patients and 
underscore the need for active TB case finding and infection control measures. The 
majority of patients also identified barriers for accessing care, including distance to 
hospital and lack of transport money. These findings support further strengthening of TB 
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There is little dispute that the global HIV/AIDS epidemic has created increasing public 
health and clinical challenges in resource-limited settings, particularly in sub-Saharan 
Africa. Of the 33.2 million individuals in the world currently living with HIV, more than 
22 million live in sub-Saharan Africa. The region also harbors a disproportionate amount 
of global mortality due to HIV, representing more than 75% of all AIDS-attributable 
deaths [1]. Within this region, South Africa assumes a sizeable share of the global HIV 
burden with more than 5.7 million HIV-positive individuals [2]. This translates into 
roughly one in four adults currently living with HIV, and a median antenatal HIV 
prevalence of 28%, reaching almost 40% in certain areas such as the province of 
KwaZulu Natal [2]. Combined with high rates of unemployment, poverty, and lack of 
infrastructure, battling the HIV epidemic in these regions has proven to be exceedingly 
challenging, particularly prior to the government-sponsored antiretroviral (ARV) rollout 
programs in 2004.   
 
Contributing to this challenge has been the concomitant rise in global tuberculosis (TB) 
incidence since 1990, with 9.2 million new cases of TB reported in 2006 alone, of which 
454,000 were in South Africa [3]. Given that HIV-positive individuals have a 
documented higher risk of developing active TB both after initial exposure and due to 
reactivation of latent TB [4, 5], it is not surprising that the rise in TB incidence has 
closely followed the HIV epidemic. TB has become the leading cause of death in HIV-
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positive persons worldwide [6] and in areas with high HIV prevalence, greater than 75% 
of all TB cases are found to be co-infected with HIV [7]. South Africa, despite being 
home to only 0.7% of the world’s population hosts 28% of the world’s TB/HIV co-
infected individuals and now has the second highest number of new TB cases in the 
world, with its annual TB incidence rising from 306/100,000 in 1990 to 940/100,000 
people/year in 2006 [3]. Although nationally, 44% of all new TB cases are found to be in 
HIV-positive individuals, in areas such as Tugela Ferry, South Africa, over 80% of all 
new TB cases are in HIV-positive individuals [3]. South Africa’s cure rate among new 
TB cases was 71% in 2006, far below the WHO recommended target of 85% [3], further 
contributing to TB transmission.   
 
The TB/HIV co-epidemic has been particularly devastating for resource-poor settings 
where the health infrastructure has been stressed by not only the demands of treating 
HIV, but also TB, which often poses a more imminent public health threat. Many systems 
have been unable to cope with the large increases in TB case volume, often resulting in 
less thorough clinical care and follow-up. In addition to the increased prevalence of 
TB/HIV co-infection are the clinical challenges that accompany these epidemics. Despite 
TB being a curable disease, mortality rates amongst TB/HIV co-infected patients 
receiving anti-TB therapy, but not yet on ARVs, have been reported to be up to 40% [8-
10]. Although many South Africans are now receiving ARV therapy through the 
government roll out program, their yearly risk of acquiring TB infection and mortality 
once infected still remains greater than HIV-negative patients [11]. Based on 2008 World 
Health Organization (WHO) estimates, only 460,000 individuals are currently on ARV 
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therapy, despite 1.7 million individuals qualifying for it according to WHO and South 
African Department of Health Guidelines [2]. This 28% ARV coverage rate leaves the 
vast majority of HIV-positive South Africans at great risk for TB-associated morbidity 
and mortality due to weakened immunity from their HIV disease.  
 
The TB/HIV co-epidemics have also created natural incubators for disease transmission. 
Congregated inpatient and outpatient settings serve as a natural means of TB transmission 
between often undiagnosed TB patients and other immunocompromised patients. 
Inadequate case detection and poor infection control practices further increase the risk of 
nosocomial transmission [4, 12].  
 
Multidrug-Resistant Tuberculosis  
Although resistance to anti-tuberculosis drugs has been present for decades, the HIV 
epidemic has fueled a rapid rise in TB cases. The subsequent overburdening of TB 
programs has resulted in inevitable increases in the incidence of multidrug-resistant 
tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). Both 
MDR-TB (defined as resistance to both isoniazid and rifampicin) and XDR-TB (defined 
as resistance to isoniazid, rifampicin, quinolones and at least one of the following: 
kanamycin, capreomycin or amikacin) pose significant threats to the effective treatment 
and control of the global TB epidemic. In 2006, 480,139 cases of MDR-TB were 
estimated to have occurred globally, representing more than 4% of all global TB cases 
[13]. The rates of MDR-TB among new TB cases in KwaZulu Natal, South Africa was 
found to be 1.7% between 2000 and 2002, the last performed provincial survey [14]. 
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However, a more recent and localized surveillance study among hospitalized patients 
reported by Gandhi and colleagues in 2006 identified 39% (185 patients) of 475 culture-
confirmed TB cases as MDR-TB and 6% (30 patients) as XDR-TB. Mortality rates 
among the XDR-TB and HIV co-infected patients were as high as 98% and most patients 
in this surveillance study were deceased before culture results confirmed the diagnosis of 
MDR or XDR-TB [15], demonstrating the need for prompt diagnosis and treatment of 
multidrug-resistant tuberculosis.     
 
The diagnosis of MDR-TB is difficult to make, especially in settings with limited access 
to mycobacterial culture, and first and second-line drug-susceptibility testing (DST). Both 
MDR-TB and XDR-TB require laboratory diagnosis, which is not performed in most 
countries until patients are failing standardized regimens. In 2006, sub-Saharan Africa 
had the lowest global uses of culture technology, with only 1% of new TB patients and 
9% of re-treatment cases receiving mycobacterial cultures [3]. Compared to standard TB 
treatment, MDR and XDR-TB treatment is less potent, more expensive, toxic, required 
for a longer duration and often unavailable in resource-poor settings. As a result, patients 
have greater mortality and lower cure rates, even when receiving treatment [16].   
 
Although drug-resistance has classically been characterized as an ‘acquired disease’ due 
to patient non-adherence or poor medical management, recent studies indicate that 
nosocomial transmission of drug-resistant strains of TB (primary disease) may play as 
large a role in MDR/XDR TB transmission [15]. Studies have shown that HIV/TB co-
infected patients are typically less infectious than their HIV-negative counterparts, due to 
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frequent pauci-bacillary disease and decreased duration of smear-positivity [7, 17, 18]. 
However, MDR-TB and XDR-TB/HIV co-infected patients tend to have prolonged 
periods of infectivity due to delayed diagnosis and ineffective treatment with 
standardized regimens [12], and may be responsible for much of the nosocomial TB 
transmission [19]. This has raised serious concerns about multidrug-resistant disease 
transmission in both hospital and community settings, and has contributed to outbreaks in 
South Africa [12, 15].  
 
Strategies for Improving TB/HIV Co-infection Treatment 
Strategies for controlling the TB epidemic in high-HIV prevalence areas have centered 
upon a multifaceted approach involving strengthening of TB programs, enhancing and 
properly implementing infection control practices, integration of TB/HIV services, and 
earlier case detection [12, 20]. Strengthening TB programs with the use of directly 
observed therapy, prompt treatment of MDR and XDR-TB, adequate case holding and 
decentralized treatment to minimize default rates can result in better treatment outcomes 
[7, 12, 20]. Enhanced and properly implemented infection control measures in both 
inpatient and outpatient settings with large numbers of TB and HIV patients are 
paramount in reducing nosocomial transmission of TB to other patients as well as to 
healthcare workers [21]. 
 
Given that many (and in some regions, most) TB patients are HIV co-infected, 
integrating separate TB and HIV health care systems facilitates the comprehensive 
management of both diseases by minimizing the number of disparate clinic appointments 
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for each patient, improving comprehensive side-effect and adherence monitoring, and 
allowing for prompt initiation of ARVs [22]. Integration of TB and HIV services also 
facilitates the universal HIV testing of all TB patients and allows earlier identification of 
active TB cases among patients with HIV by screening for TB suspects [7]. Currently 
only 1/3 of all South African TB patients receive HIV testing, resulting in missed 
opportunities for HIV diagnosis and treatment [3] and conversely most HIV programs do 
not employ routine TB screening among patients seen for HIV related reasons. Given that 
earlier case detection reduces time to TB diagnosis, resulting in both better clinical 
outcomes and possibility for reduced transmission of TB to others, active case finding in 
the community and clinical care settings (especially among HIV positive individuals) and 
prompt utilization of diagnostic methods are essential components of TB control 
programs.   
 
Barriers to Early TB Diagnosis and Case Detection  
Efforts directed at improving TB case detection and earlier diagnosis are essential in 
curbing the global TB epidemic, especially in areas of high HIV-prevalence. However, 
these efforts face a myriad of challenges. Studies estimate that most patients (in both high 
and low TB prevalence regions) experience 60 to 90 days of delay from the onset of TB 
symptoms to diagnosis and treatment [23]. Indeed, in one study from Ghana, total delay 
to diagnosis exceeded 6 months in 44% of patients [24]. Patients with delayed diagnosis 




Although most delays are a combination of patient delay (time from onset of symptoms 
to contact with a health care provider) and health system delay (time from contact with a 
health care provider to diagnosis and/or treatment initiation), the contribution of each to 
total delay time can vary. In some studies, patient delays were much longer [28-31] 
whereas in others, health care provider delays were more common [24, 27, 32], likely 
reflecting differences in the characteristics of local healthcare systems and patient 
populations. For example, in Ghana, provider delay was highly correlated with failure to 
perform sputum microscopy [24]. Given the myriad differences between various 
populations and health systems, it is not surprising that studies describing risk factors for 
delayed diagnosis reach disparate (and sometimes contradictory) conclusions. For 
example, one systematic review of 58 studies by Storla and colleagues demonstrated that 
certain risk factors such as other lung disease and negative sputum smear were positively 
associated with delayed diagnosis in some studies, but negatively in others [23]. In some 
studies, a risk factor, such as gender, was associated with greater patient delay in some 
populations (e.g. men postpone seeking care for longer than women [33]) and greater 
health system delay in others (e.g. females had a longer time to diagnosis once they had 
sought care [23]). As a result, interpreting the cumulative effect of such risk factors on 
patient delay can be difficult. Although there are certainly common trends in delayed 
diagnosis across regions, as discussed, some findings may be difficult to extrapolate or 





There are a variety of patient-related factors associated with the delayed diagnosis of TB. 
The information-motivation-behavioral skills (IMB) model, used most frequently in ARV 
adherence studies [34-36], provides a useful framework to understanding these factors. 
The IMB model was first developed by Fisher and Fisher as a means to understand and 
predict HIV-related risk behaviors, and design appropriate preventative interventions [37, 
38]. As the authors explain, “To the extent that individuals are well informed, motivated 
to act and possess the requisite behavioral skills for effective action, they will be likely to 
initiate and maintain health-promoting behaviors and to experience positive health 
outcomes. In contrast, to the extent that individuals are poorly informed, unmotivated to 
act, and lack behavioral skills required for effective action, they will tend to engage in 
health risk behaviors and to experience negative health outcomes [39].” Organizing 
patient-related factors associated with delayed TB diagnosis in terms of patient 
information about TB, motivation to seek care for TB symptoms, and behavioral skills 
necessary to access and initiate care provides a framework that can be readily used to 
design interventions to reduce delayed diagnosis.   
   
Information 
Levels of knowledge about TB can have important effects on TB diagnostic and 
therapeutic success, but vary widely across different settings. In one Tanzanian study, 
84% of patients could describe how TB was transmitted and 75% identified its 
association with the HIV/AIDS epidemic. All patients thought that TB could be cured 
with proper treatment [40]. In contrast, only 14% of community members in Limpopo, 
South Africa thought tuberculosis had a biomedical cause, although 91% preferred 
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biomedical treatment [41]. In a high-HIV prevalent area in Thailand, patients were very 
knowledgeable about HIV but lacked knowledge about TB. They attributed TB 
symptoms such as cough, fever and weight loss to symptoms of AIDS [42]. Although 
limited knowledge of TB among TB patients did not affect treatment adherence in one 
study [32], larger studies (including one meta-analysis) have generally concluded that 
poor patient knowledge about TB (particularly about TB treatment, its side effects, 
duration, and importance of completing therapy) are associated with poor patient 
adherence [43, 44].   
 
With regards to delayed TB diagnosis, deficits in patient information and misconceptions 
about TB although in some settings have been shown to have no impact on patient delay 
[45], have generally been found to prolong patient delay [23, 28].   
 
Motivation 
With regards to motivation, community perceptions about TB and HIV disease and 
patients’ personal beliefs about health care can often serve as barriers to seeking care for 
TB. Patients from communities in which HIV and tuberculosis continue to be stigmatized 
report hesitation to seek care due to social stigma, and personal fear of being diagnosed 
with TB and/or HIV [42]. Patient beliefs about health care and where they initially seek 
health care are also very prognostic of patient delay [23]. The use of traditional healers is 
particularly relevant in certain communities such as South Africa, and health authorities 
have made increasing efforts to incorporate them into official TB diagnosis programs. 
The use of healers is intimately tied to patient health beliefs and attribution of disease as 
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well as perceptions of TB treatment. As one qualitative study in Kenya revealed, “TB 
treatment is perceived as long, agonizing and cumbersome. Traditional treatment is 
considered a valid alternative to modern treatment, believed to be as effective and much 
shorter.” [46]. A study conducted in rural South Africa by Barker and colleagues revealed 
that 51% of 133 TB patients had visited a traditional healer prior to visiting a Western-
trained health care practitioner. Patients who had visited a traditional healer delayed 
seeking anti-tuberculosis therapy (median 90 days) compared to patients who 
immediately approached government health centers (median 21 days) and also had worse 
performance status and increased mortality (31% vs. 12%, P=0.04) [47].  
 
Socioeconomic factors are the most frequently cited risk factors for patient delay, 
especially given the convergence of poor education and poverty with the global TB and 
HIV epidemics. Many of these factors are closely linked to poor access to healthcare and 
fewer healthcare options (discussed below). Patients living in rural areas and/or far 
distances from health care centers were significantly more likely to delay seeking care 
[24, 26, 28, 29, 31, 33, 45] and were also less likely to be diagnosed even once in care 
[29]. Unemployment and poverty were also associated with patient delay [23, 48] 
although not in all settings [45].  
 
Alcoholism [33, 48, 49] and drug use [50] are also associated with increased delay as is 
severe underlying illness [45], possibly due to impaired judgment and inability to travel 





With regards to behavioral skills, even with appropriate information about TB, and 
sufficient motivation to seek care, it is necessary that patients know when and where to 
seek care for TB. Many patients assume that their symptoms will eventually resolve and 
fail to seek care even with persistent symptoms [23, 48]. The (mis)attribution of disease 
by patients also often results in self-treatment [46, 48, 51, 52] which delays entry into the 
health care system. For example, TB patients at a referral hospital in Kampala who 
attributed their symptoms to smoking were 5.4 times as likely to experience diagnostic 
delay than patients who did not [49].  
 
Behavioral skills related to where to seek care are also prognostic of delayed diagnosis 
and patient outcomes. Where patients seek initial care varies by location, with patients in 
Kampala initially approaching private pharmacies (39%), private clinics (37%) and 
government health clinics (14%) [49] while in rural South Africa the majority of patients 
attended a public hospital or clinic with only 13% seeking care with a private practitioner 
[30]. Patients who are unsure where to seek care also experience diagnostic delay [48] as 
are patients who endorse poor perceptions of local health services [45, 46]. Often, 
patients make multiple visits to various health care providers without receiving the 
correct diagnosis. In particular, untrained staff at primary health care posts with limited 
resources [27], private practitioners [28, 32, 33, 45, 51], and traditional healers [30, 47] 
were identified as being primarily responsible for not establishing a correct diagnosis and 
subsequent delay [23]. In one study from Burkina Faso, more than 94% of all patients 
received multiple courses of short-term antibiotics with repeated visits to the same 
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clinical providers [23]. In another study in Kampala, 81% of all patients had contacted 
someone outside of the hospital within four weeks of appearance of symptoms, but 
diagnosis was delayed due to missed opportunities by private practitioners and public 
hospitals (delay was minimized when patients presented to the National Tuberculosis 
Program) [49]. These findings suggest that educating patients about when they should 
seek clinical care, and providing the skills necessary to know where they should go for 
adequate care might reduce some patient delay. Educating clinical providers about TB, 
and when to refer patients to national TB programs would likely reduce system-related 
delay. 
 
Characteristics of Illness 
Characteristics of illness can also influence delay in diagnosis. Patient health-related 
factors such as underlying disease, symptoms, and smear status often complicate TB 
diagnosis, resulting in both patient and health system delay. In resource-limited settings   
and particularly among HIV-infected patients, TB may have an atypical presentation, 
confounding correct diagnosis. Sputum smear-negative patients tend to have longer 
health system delay, likely due to difficulty with diagnosis (see: Limited Diagnosis, 
below). Similarly, underlying pulmonary disease (such as neoplasia, chronic cough, or 
silicosis) often complicates diagnosis and is associated with delayed diagnosis, as are 
non-TB symptoms in HIV positive patients who may have a variety of medical 
complaints [50]. In Kenya, health care providers often attributed TB symptoms such as 
cough or fever to malaria or a viral respiratory tract infection and patients were not 




Limited Diagnostic Facilities 
Most national tuberculosis programs in sub-Saharan Africa have adopted WHO DOTS 
TB diagnostic guidelines and rely primarily on sputum microscopy for diagnosis. The 
sensitivity of sputum smear for detecting M. Tb has been reported to be between 34% to 
94% [53], although the sensitivity can be greatly reduced in operational settings with high 
TB case loads and few laboratory workers due to the time required to properly read each 
smear. Smear sensitivity can be increased by up to 10% with the use of fluorescence 
microscopy [53], but is often only available at reference laboratories. Although some 
studies have documented no difference in smear-positivity rates between HIV-positive 
and HIV-negative patients [54], many studies have shown an increasing percentage of 
smear-negative TB cases in high HIV-prevalence areas [55, 56]. This association is 
thought to be a result of paucibacillary disease associated with decreased immunity, as 
well difficulty differentiating TB from other HIV-related lung pathology [57]. Of 
worldwide TB cases in 2006, 56% were classified as “smear-negative” [3]. One recent 
review of fifteen studies by Getahun and colleagues reported smear-negative rates 
ranging between 24-61% [58]. In patients with smear-negative sputum samples, national 
protocols often advocate for the use of short-term antibiotic treatment followed by chest 
radiography if there is no improvement. Some evidence indicates that patients may have 
improvement or resolution of respiratory symptoms with antibiotics, even if they have 
undiagnosed TB [58]. In addition, the accuracy and sensitivity of chest x-ray based TB 
diagnosis in HIV positive patients is markedly diminished due to less frequent cavitary 
disease, and up to 14% normal radiographs among TB/HIV co-infected patients [59-61]. 
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The challenges of smear-negative TB are not only its association with delayed diagnosis 
and increased mortality compared to smear-positive TB [58, 62], but also the 
infrastructural questions it can raise regarding quality of laboratory services, adequate 
sputum collection and smear preparation. Inadequate laboratory technique can reduce 
smear microscopy sensitivity, especially in rural, resource-poor settings with little 
technological support. It should also be noted that none of these diagnostic 
methodologies, other than culture with subsequent DST would provide a diagnosis of 
MDR or XDR TB.  
 
Thus TB cases missed due to the poor sensitivity of sputum microscopy, chest x-ray and 
clinical symptoms amongst HIV-positive patients, are often only detected through 
mycobacterial culture, which remains the gold standard for diagnosis. The sensitivity of 
liquid culture using the Bactec MGIT system has generally been shown to be higher than 
solid culture (93% vs. 82% respectively) [63]. However, most national TB programs 
based on WHO DOTS guidelines, such as South Africa, restrict the use of culture to 
specific TB populations, (e.g. re-treatment cases or patients failing therapy [64]), and 
even these guidelines are not always followed [3]. Many experts have suggested that the 
WHO DOTS strategy [3], which primarily targets the finding and treatment of smear-
positive TB cases, is not adequate for high HIV-prevalence settings [6, 20, 58], and have 
advocated for the development of better diagnostics and more comprehensive use of 
culture. Mathematical models have demonstrated that expanding culture and DST in both 
new and previously treated TB cases could result in an 18% decrease in TB mortality and 
prevent almost 50% of MDR-TB deaths, and could be cost-effective [65, 66]. However, 
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current laboratory methods using solid agar culture or newer liquid culture systems (e.g. 
the Mycobacteria Growth Indicator Tube (MGIT), Becton Dickinson) with subsequent 
drug-susceptibility testing, as is done in South Africa, take 6-8 weeks, and require 
clinician follow-up for results. In some settings in South Africa, this has proven to be too 
demanding and clinicians rely purely on clinical diagnoses, which may not be accurate 
and miss MDR/XDR-TB diagnoses [67]. In addition, given that the median survival time 
for the XDR-TB patients in the Tugela Ferry, South Africa outbreak was just 16 days 
from time of sputum collection [15], culture times of 6-8 weeks are often too long to 
prove useful.  
 
Moreover, access to culture and DST (especially for second-line anti-tuberculosis 
therapy) is not available in most resource-poor settings. In South Africa, culture and DST 
is only performed at the centralized tuberculosis reference laboratories, often instituting 
further system delays involving transportation of samples and results [64]. Certain new 
rapid diagnostic tests appear promising, such as the microscopic-observation drug-
susceptibility (MODS) assay developed in Lima, Peru. The non-proprietary test has been 
shown to have greater sensitivity than the gold standard solid agar or liquid culture 
methods, with greater than 99% specificity. It’s minimal cost, 7 day median time to 
culture result and MDR-TB diagnosis, and ability to be performed in low-resource 
settings with microscopy capacity could prove to be a solution to many of the current 
laboratory diagnostic challenges [68].  
 
Limited Case Finding 
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Most TB programs employ passive case finding, relying on patients to appear at medical 
faculties for TB treatment and diagnosis. As can be readily appreciated from the 
information above, this will result in the late diagnosis of TB cases, if at all. A more 
aggressive, active case finding (whereby all patients are screened for signs and symptoms 
of TB) approach may identify patients earlier in their disease. Prior active case finding 
studies conducted in sub-Saharan Africa have revealed rates of active TB to be as high as 
10% among HIV-positive populations [69-72]. Without the active case detection methods 
utilized by these studies, many of these cases would go undetected due to early stages of 
disease or diagnostic challenges as described previously. Although the WHO now 
recommends intensified case-finding (active screening of all patients for signs and 
symptoms) for TB among all HIV-positive individuals in congregate settings [71], the 
current DOTS policy which relies on passive TB case finding (where symptomatic 
patients self-present to health care centers), is still utilized in many regions [3]. One 
mathematical model by Currie and colleagues compared the impact of finding and 
treating active tuberculosis with three prevention methods (ARV therapy, treatment of 
latent TB infection and reduction of HIV transmission) on long-term TB control in high 
HIV prevalence regions. According to their model, TB case detection and treatment 
remained the most effective method to controlling the number of TB cases and TB-
related mortality. In South Africa, they predicted that a 1% increase in annual case 





Recognizing the significant impact that TB case detection can have on decreasing 
tuberculosis burden, experts have long advocated for expansion of active case finding, 
especially among vulnerable populations [74, 75], and several recent studies have 
demonstrated the feasibility [70] and benefit of active case-finding in resource limited 
settings [69, 70, 72]. One large study in urban South Africa screened 762 randomly 
selected adults in the community using sputum microscopy and TB culture and found a 
TB prevalence of 3.3%. Among the 174 HIV+ subjects, this prevalence rose to 9.2%. 
Interestingly, among the 5% of HIV/TB co-infected patients who were previously 
undiagnosed, 67% of the patients denied cough, night sweats, and weight loss and only 
25% had two or greater symptoms (a non-statistically significant difference from the 22% 
of non-TB cases who also endorsed two or greater symptoms) [72]. Another study in 
Tanzania evaluated 93 ambulatory HIV-positive patients participating in a tuberculosis 
vaccine trial using sputum microscopy and culture. Of the 14 (15%) TB-positive patients, 
4 were deemed to have ‘subclinical tuberculosis’ with no signs or symptoms of TB or 
abnormal chest x-ray, but positive sputum cultures for M. Tuberculosis suggesting that 
symptom screening and CXR alone may not be sufficient to identify all TB cases [69]. 
Active case-finding also facilitates the earlier diagnosis of MDR and XDR-TB [15], 
likely leading to decreased mortality and TB transmission, although data on such 
outcomes are limited. 
 
Given the impact of delayed diagnosis on patient outcomes as well as its public health 
threat in terms of community and hospital-based TB transmission, it is imperative that 
efforts be made to diagnose and initiate TB treatment as soon as possible. There is a 
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particularly urgent need for earlier diagnosis in settings with a high prevalence of HIV 
and MDR/XDR-TB, due to increased TB transmission as well as exceedingly high 
mortality rates. The risk of nosocomial transmission of unrecognized TB, particularly 
MDR/XDR-TB poses a significant threat to both the immunocompromised patient 
population in such settings as well as health care workers exposed on a daily basis, many 
of whom may also be HIV-positive.    
 
Although rapid TB diagnostics are certainly a component of this strategy, the 
development, validation, and implementation of such tools is unlikely to occur in the 
immediate future. However, there are many other factors as described above that 
contribute to delayed patient diagnosis and can be readily addressed in resource-limited 
settings. There is a need to initiate active-TB case finding in settings of high HIV-
prevalence, such as outpatient ARV clinics. Such case finding would not only allow for 
greater detection of undiagnosed TB, but also potentially reduce nosocomial transmission 
and establish prevalence rates of drug-susceptible and drug-resistant TB that can better 
inform infection control practices. In addition, elucidating what patient barriers exist 
within each community would allow local health officials to design appropriate 
interventions to bring patients into care sooner. Tugela Ferry, South Africa, is of 
particular interest due to the high prevalence of HIV and MDR and XDR-TB first 
recognized in 2005 and documentation of nosocomial TB transmission [15]. Given the 
rapid scale-up of antiretroviral therapy over the past five years, the increasing number of 
HIV-positive patients receiving care at this rural district hospital, and the confluence of 
drug-susceptible and drug-resistant TB, it is essential to better define the prevalence of 
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active TB among those receiving HIV care and also to characterize the knowledge of TB 
amongst this population. To accomplish this, we have designed and implemented a 
prevalence survey among “TB suspect” attendees of an ARV clinic and linked to this a 
survey of information, motivation and behavioral skills regarding TB among inpatients 









































1. Characterize the prevalence of undiagnosed drug susceptible and drug resistant TB 
amongst ambulatory HIV patients attending an antiretroviral clinic in rural South 
Africa 
• We hypothesize that there are high rates of undiagnosed TB in this setting, with 
potential nosocomial transmission of drug-susceptible and drug-resistant TB to 
vulnerable immunocompromised patients, and increased occupational hazards 
for health care workers. 
2. Characterize symptoms and risk factors associated with TB diagnosis 
• We hypothesize that our HIV-positive patient population may have atypical TB 
symptoms and that factors such as prior hospitalization and history of TB may 
be important given the high prevalence of MDR and XDR-TB.  
3. Identify barriers resulting in delayed diagnosis of TB among hospitalized and 
ambulatory clinics at a rural district hospital in South Africa. 
• We hypothesize that distance from COSH, cost of transport, and community 
stigma related to HIV and TB likely serve as patient barriers to seeking care and 












This study was conducted at the Church of Scotland Hospital (COSH), in the rural town 
of Tugela Ferry, located in the Msinga sub-district of KwaZulu Natal (KZN) Province, 
South Africa, approximately 150 km from the port of Durban. The local population 
comprises approximately 200,000 traditional Zulu people who still live in mud and straw 
traditional rondovals in widely separated family compounds scattered over almost 2,000 
km2. The district is mountainous with only one tarred road running through it, making 
transportation extremely difficult. Msinga is one of the poorest regions in the nation, with 
the vast majority of the population lacking electricity, sewage facilities, clean water, and 
adequate education. Unemployment rates in the region exceed 60%, and greater than 75% 
of the households in the region are female-run as most men of working age flee to urban 
areas in search of work.  Antenatal HIV prevalence has been estimated to be 
approximately 40%, and greater than 40% of all hospital admissions are among HIV-
infected individuals. The area has one of the highest TB incidences in the world, with 
more than 1,000 cases/100,000 population.  
 
Medical care is provided at the Church of Scotland Hospital, a former mission hospital 
now a 355-bed provincial government district hospital. More than 1,200 new cases of TB 
are diagnosed at COSH every year. Patients also receive health care at 13 satellite 
primary care clinics, as well as COSH, which serves as the sub-district referral hospital. 
In addition to providing inpatient care in the medical, tuberculosis, surgical, and 
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maternity wards, COSH also provides outpatient care through an emergency department, 
urgent visit clinic, and a dedicated HIV/AIDS antiretroviral clinic. COSH was the site of 
an XDR-TB outbreak first documented in 2005[76],  and continues to have high 
prevalence rates of MDR and XDR-TB compared to the rest of the province. Between 
2005 and 2007, there were 654 identified cases of multi-drug resistant tuberculosis of 
which 382 (59%) also met the definition of XDR-TB [76]. There is also substantial 
evidence to indicate that the high rates of MDR and XDR-TB at COSH are the result of 
nosocomial transmission to immunocompromised patients [15].   
 
Since 1993, COSH has provided a government-sponsored tuberculosis program using the 
WHO DOTS strategy [77]. Patients are diagnosed with TB largely using clinical 
evaluation, chest x-ray, and sputum microscopy for acid-fast bacilli, which is performed 
at the COSH laboratory on-site, based upon South African National Tuberculosis 
Guidelines [64]. Given the high prevalence of multi-drug resistant and extensively-drug 
resistance tuberculosis discovered in this region in 2005 [15], efforts have been made to 
ensure that sputum culture is obtained not only from individuals failing anti-TB therapy, 
or with TB relapse, which is South African standard practice [64],  but also from all 
patients newly diagnosed with TB. Sputum samples for culture and drug-susceptibility 
testing (DST) are transported to a central tuberculosis laboratory located in Durban. All 
sputum samples are processed using the MGIT liquid-culture based system and DST is 
performed using the 1% proportion method (these methods are described in greater detail 
below in Laboratory Methods). Culture and DST results are typically available within 
 23 
 
4-6 and 8-12 weeks respectively. Printed results are delivered to COSH weekly, and are 
additionally available online through the provincial Department of Health intranet.  
 
Due to lack of personnel and the rural distribution of the patient population, patients are 
only seen by healthcare workers monthly to receive medication refills, and are expected 
to otherwise self-administer their daily anti-tuberculosis therapy. TB patients are started 
upon the standardized four-drug regimen of isoniazid, rifampicin, ethambutol, and 
pyrazinamide for a two-month intensive phase, followed by isoniazid and rifampicin for a 
four-month continuation phase.  
 
Antiretroviral therapy was first introduced at COSH under a government program in 
March 2004. Patients with either WHO Stage IV disease or CD4-positive T-lymphocyte 
(CD4) counts less than 200 cells per mm3 were eligible to receive free therapy. In 
addition to free voluntary counseling and testing (VCT) of HIV available at COSH, 
patients are often tested for HIV in the community or at the peripheral clinics and then 
referred to COSH for initiation of treatment. The ARV clinic has provided ARV therapy 
to more than 3,500 patients and now initiates ARVs in more than 150 patients monthly. 
Patients self-administer ARVs at home with the assistance of family members and 
community healthcare workers as treatment supporters and return to the clinic monthly 
for medication refills. Although the exact prevalence of active TB among ARV clinic 
patients is unknown, given the high rate of TB-HIV co-infection at COSH, (more than 
80% of all TB patients at COSH are HIV co-infected) the hospital has aimed to further 
integrate TB-HIV care by setting up a “TB station” in its ARV clinic where ARV clinic 
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patients can be screened for TB, initiated on anti-tuberculosis therapy, and receive 
monthly follow-up monitoring during their routine ARV clinic visits.   
 
Study Design 
This study was nested within a larger study evaluating the microscopic-observation drug-
susceptibility (MODS) assay, a new rapid-diagnostic test for TB [68] that has not been 
validated in a setting with high HIV-prevalence. The study population for our study was 
derived from patients being evaluated in the MODS study. Our study was a cross-
sectional cohort study of predominantly HIV-positive patients with TB symptoms at a 
rural hospital in KwaZulu Natal, South Africa. Two linked cross-sectional cohort studies 
were designed to identify the prevalence and social covariates of TB among this 
population. The first study was designed to screen all patients attending an outpatient 
ARV clinic for undiagnosed TB and the second to assess the barriers that might result in 
delayed diagnosis of TB among both inpatients and outpatients at COSH, using a 
questionnaire based upon the information, motivation and behavioral skills model [36, 
37] (see Introduction). The complete questionnaire is included in Appendix A.  
 
Case Definitions 
Only patients who were deemed to be “TB suspects” were enrolled in this study. “TB 
suspects” were defined as those individuals with either cough (of any duration) or two or 
more of the following TB symptoms: chest pain, fever, night sweats, weight loss or 
shortness of breath. People who did not meet these criteria were not considered TB 
suspects and were excluded from participating in this study.  
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 TB screening:  
All patients enrolled in this study were classified as “TB case” or “non-TB case” using 
revised WHO case definitions for HIV-prevalent settings [78]. A “TB case” was defined 
as any individual with at least one of the following: a) a positive sputum smear for AFB 
by the Ziehl Neelson method; b) a positive sputum smear for AFB by the concentrated 
method; c) a positive Middlebrook 7H10 culture for M. tuberculosis; or d) a positive 
MGIT culture for M. tuberculosis. All remaining patients were deemed to be “non-TB 
cases.”  
 
All “TB cases” were further categorized according to drug-susceptibility testing results. 
Patients with fully susceptible resistance patterns, or resistant to one or more drugs, but 
not isoniazid and rifampicin were deemed “drug-susceptible” TB. Patients resistant to 
both isoniazid and rifampicin were deemed “MDR tuberculosis” and patients additionally 
resistant to a fluoroquinolone and either aminoglycosides (amikacin, kanamycin) or 
capreomycin (or both) were deemed “XDR tuberculosis.”   
 
Some patients enrolled in the study were called “MDR-suspects.” These individuals were 
defined as patients who had been on anti-TB therapy for two or more months, with one or 
more continued TB symptoms.  
 
Delayed diagnosis: 
All patients self-reported the time between onset of symptoms to first presentation to 
COSH from the following categories: <2 weeks, 2-4 weeks, 1-3 months, 3-6 months, 
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6months-1year and >1 year. All patients who presented for care after >1 month of 




The primary outcome measure was the number of cases and prevalence of drug-
susceptible and drug-resistant tuberculosis amongst this HIV-positive clinic population. 
Secondary outcome measures were:  
a) Presence of TB related Symptoms: We compared the presence of various TB 
symptoms among the TB cases and non-TB cases;  
b) Presence of TB risk factors: We compared TB risk factors among the TB cases and 
non-TB cases, including sex, age, TB history, TB contacts, and history of hospitalization; 
c) Effect of Socioeconomic Status on TB Status: We compared socioeconomic factors 
among TB cases and non-TB cases, including electricity, education, employment, water 
sources, cooking facilities, and cost of transport; and  
d) AFB smear: We assessed the sensitivity of AFB smear (compared to culture) in 
diagnosing TB in an HIV-positive population, comparing direct smears done at the rural 
district hospital and the provincial referral laboratory, as well as direct versus 
concentrated microscopy.  
 
Delayed Diagnosis: 
The primary outcome measure for this survey was the % correct survey responses 
regarding TB information amongst predominantly HIV-positive individuals presenting 
for care at this rural district hospital. We sought to stratify this level of knowledge across 
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several populations, namely: patients on ARVs who had received education and training 
regarding opportunistic infections, including TB; patients currently or previously on 
tuberculosis treatment who had also received education regarding TB; and patients who 
delayed seeking care for >1 month from the onset of symptoms.  
Secondary outcome measures included: 
a) Presence of motivational barriers in seeking care: We described a variety of 
motivational barriers including cost of transport to COSH, stigma related to HIV and TB 
and personal health beliefs and their relation to delayed diagnosis; 
b) Presence of behavioral skills barriers in seeking care: We described behavioral skills 
barriers regarding patients’ ability to know when and where to seek care for TB 
symptoms; 
c) Proportions of patients with Delay >1 month in seeking care: We described the degree 
of delay among all patients seeking care; and  
d) Characteristics of patients delayed care seeking: We described characteristics that 
were associated with patients who delayed seeking care for their symptoms for >1 month.  
 
Study Participants 
All hospitalized inpatients, or outpatients presenting to the ARV Clinic or Outpatient 
Department (OPD) who were “TB suspects” were considered for enrollment in this study. 
“TB suspects” were defined as individuals who had either cough (of any duration), or 2 
or more of the following TB symptoms: chest pain, weight loss, fever, night sweats, or 




Inclusion criteria included: patients 18 years of age or older, who were able to produce 
sputum samples, consented to participate in the study, and met the definition of “TB 
suspect” as defined above. All patients currently on anti-tuberculosis therapy for greater 
than 2 months with one or more persistent TB symptoms were deemed eligible to 
participate.  
 
Exclusion criteria included: patients who were currently on tuberculosis therapy for 
greater than 2 days or less than 2 months, or had taken medications with anti-
mycobacterial activity (e.g., fluoroquinolones, macrolides or aminoglycosides) within the 
past week. Inclusions and exclusion criteria related to duration of anti-tuberculosis 
therapy and exposure to antibiotics with anti-mycobacterial activity were utilized because 
such criteria were required for the larger MODS study, of which this study was a subset.  
 
Data Collection 
Patients were enrolled for this study from 1 February 2008 through 31 August 2008. 
Trained bi-lingual research personnel performed a standardized symptom screening and 
survey on all patients presenting to the OPD or ARV clinic, as well as all patients 
hospitalized in the medical, tuberculosis and surgical wards. Patients were asked in Zulu 
using a standardized four-page, 40-question protocol survey about the presence of cough, 
hemoptysis, fever, weight loss, night sweats, shortness of breath, chest pain, diarrhea, 
appetite loss, and fatigue. Patients were also asked standardized questions assessing their 
levels of information, motivation, and behavioral skills regarding tuberculosis and HIV, 
their knowledge of tuberculosis symptoms, and possible causes of delayed presentation 
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and barriers to seeking care.  Most questions were closed-ended. Questions about TB 
knowledge assessed patients’ awareness about TB treatment, MDR-TB, association with 
HIV, and TB symptoms. Questions about patient motivation assessed a variety of barriers 
to seeking TB care, including levels of HIV and TB-related stigma, willingness to be 
hospitalized for treatment, distance from the hospital, financial means, and awareness 
about side effects related to anti-tuberculosis therapy. The survey also assessed patients’ 
health beliefs, including what they thought was causing their symptoms, if they had been 
seen prior to their current visit at the hospital and if they had had negative experiences 
with health care providers in the past. Patient’s behavioral skills were evaluated through a 
number of questions evaluating pill-taking ability, pill-storage, sources of support and 
where they generally seek care.   
 
Additional data was collected (and verified with medical records when available) on 
basic demographics and risk factors for TB such as prior TB, hospitalizations and HIV 
status. HIV testing was not performed as a part of this study, but all patients whose HIV 
status was unknown were encouraged to be tested. HIV positive patients with unknown 
or non-recent CD4 counts were referred for blood draws according to South African 
Department of Health Guidelines.  
 
All patients submitted one to three sputum samples for mycobacterial culture and DST. 
One sample was sent for direct and concentrated microscopy, culture and DST to the 
research laboratory at the Nelson Mandela School of Medicine in Durban for the 
purposes of this study. The second and third samples were utilized for same-day sputum 
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microscopy performed at COSH and for culture and DST performed at the provincial 
referral laboratory in Durban, respectively as is routinely done for TB suspects at COSH. 
All sputum specimens were non-induced and collected at the time of enrollment for all 
outpatients, and within a twenty-four hour period (as produced) for hospitalized patients. 
Sputum samples collected for culture were stored at 4° C for a maximum of 48 hours 
prior to weekly transport to the referral laboratories in Durban.  
 
Laboratory Methods 
The methods for sputum decontamination, culture, and drug-susceptibility testing in this 
setting have been previously described and published [15]. All sputum samples were 
digested by the N-acetyl-L-cysteine method with a small portion reserved for standard 
Ziehl-Neelson smear and concentrated microscopic sputum examination for acid-fast 
bacilli (AFB).  The re-suspended sediment was then divided for two standard culture 
techniques (Middlebrook 7H10 agar plates and Bactec MGIT-960 broth). Agar plates 
were sealed in CO2-permeable bags and incubated in 5% CO2 at 37°C and read at three 
weeks and six weeks. Cultures that exhibited no growth by 6 weeks, or became 
contaminated were discarded. MGIT broth tubes were incubated at 37°C in an automatic 
incubator and continuously monitored for 42 days. Each positive MGIT sample also 
underwent acid-fast microscopy for confirmation, and those that were AFB-positive were 
sub-cultured on Middlebrook 7H10 agar. MGIT cultures that exhibited no growth by 42 
days were discarded, and contaminated cultures were re-decontaminated and re-cultured. 
All positive cultures were identified as Mycobacterium tuberculosis by using niacin and 




Drug susceptibility testing was performed on all positive isolates using the 1% 
proportional method on Middlebrook 7H10 agar. All isolates were tested for 
susceptibility to isoniazid (0.2ug/mL), rifampicin (1.0ug/mL), ethambutol (5.0ug/mL), 
streptomycin (2.0ug/mL), kanamycin (5.0ug/mL) and ofloxacin (2.0ug/mL), similar to 
the national referral laboratory. In cases where culture or drug-susceptibility testing 
results at the research laboratory were repeatedly contaminated or failed to grow, results 
from same-day sputum samples sent to the provincial referral laboratory were utilized.  
 
Data Analysis 
South African and American research assistants performed dual-data entry of all 
laboratory results and survey forms into a Microsoft Access database. All discrepancies 
were reconciled using source data on a line-by-line basis.  
 
Statistical Methods 
We performed descriptive statistics to characterize the study population with regards to 
relevant demographic, clinical and microbiologic information.  Bivariate analyses were 
used to compare demographic and clinical characteristics between TB and non-TB cases, 
as well as sub-group analyses based on CD4 cell count; duration on ARV-therapy; 
individuals failing current TB-therapy (MDR-suspects); reasons for coming to clinic; and 
type of tuberculosis (drug-susceptible vs. MDR/XDR). Means and medians were 
compared using T tests and Wilcox Rank Sum tests, respectively. All dichotomous 
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variables were compared using Chi-square tests. All analyses were performed using 
StataSE Version 10.0 [Stata, College Station, TX, USA].  
 
Patient Care 
Patients were treated for TB according to clinical judgment and South African National 
TB guidelines [64]. As culture and DST results became available, they were shared with 
the patient’s clinician to be incorporated into the patient’s care plan. 
 
Ethics and institutional review  
This study was approved by the Human Investigation Committee at the Yale University 

















TB Screening  
TB Prevalence and Demographics  
A total of 272 ARV clinic patients were enrolled for this study between 1 February 2008 
and 31 August 2008. Nine patients who were not HIV positive were excluded from 
analysis in order to examine the target population of this clinic. Of these 9 patients, 4 had 
unknown HIV status and 5 were HIV-negative, but had been long-time patients of one of 
the ARV clinic physicians and were thus seen at the ARV clinic for other medical 
conditions. Of the 263 remaining patients that were included in this study, 52 (20%) were 
sputum-smear positive for AFB or culture-positive for M. tuberculosis and were 
determined to be “TB cases” and 211 (80%) were determined to be “non-TB cases.”    
 
Of the 52 TB cases, 24 (46%) were smear-positive for AFB by either direct microscopy 
for concentrated fluoroscopy at the research laboratory in Durban. Of the 24 smear-
positives, 20 were also culture-positive by either solid or liquid culture, or both, and 4 
were smear-positive but culture-negative by both methods. Of the 52 TB cases, 28 (54%) 
TB cases were smear-negative, but culture-positive by either solid or liquid culture, or 
both. Sputum microscopy results from the local COSH laboratory were available for 13 
of the 24 smear-positive cases. 12/13 (92%) smear-positive cases were found to be 
smear-negative at COSH, with only 1/13 (8%) positive for AFB. Using our definition of 
“TB case” as the gold standard, mycobacterial culture, reference laboratory-based sputum 
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microscopy and COSH-based sputum microscopy had sensitivities of 92%, 46% and 8% 
respectively, as described in Figures 1.1-1.3. 
 
Figure 1.1: Culture result compared to TB Status 
 
 
 TB Status  
Smear Result + --  
+ 24 0 Sensitivity: 46% 
-- 28 211 Specificity: 100% 
Figure 1.2: Smear result compared to TB Status 
 
 
 TB Status  
COSH Smear 
Result + --  
+ 1 0 Sensitivity: 8% 
-- 12 109 Specificity: 100% 
Figure 1.3: COSH smear result compared to TB status 
 
DST results were available for 46/52 TB-cases (88%); 6 DST results were unavailable 
due to repeated contamination or failure of culture growth. Of the 46 TB cases for which 
DST results were available, 33 (72%) were drug-susceptible TB, and 13 (28%) were drug 
resistant. Of these 6 (13%) were MDR-TB and 7 (15%) were XDR-TB (see Figure 2).  
 TB Status  
Culture Result + --  
+ 48 0 Sensitivity: 92% 




Figure 2: Distribution of DST Results N=46 
 
The demographic and clinical characteristics for TB and non-TB cases are described in 
Table 1. Although men comprised only 1/3 of the study population, they accounted for 
52% of all TB-cases. The difference in TB rates between men and women was 
statistically significant (p=0.0126). Median ages were not significantly different 
(p=0.087) between the two groups; the median age and age ranges for the TB-case and 
non-TB case groups were 36 years (24-71 years) and 39 years (20-63 years), respectively. 
Median CD4 cell counts for the TB-case group (140 cells/mm3) were significantly lower 
than for the non-TB case group (242 cells/mm3, p=0.0004). 60% of TB-case group had 
CD4 counts <200 cells/mm3 whereas only 34% of non-TB case group had CD4 counts 
<200 cells/mm3. Patients in the TB-case group were also less likely to be on ARVs, with 







Table 1: Demographic Characteristics of ARV Clinic TB and non-TB cases 
A 9 non-HIV positive patients were excluded from analysis  










Sex      
Female 175 (67) 25 (48) 148 (70) 0.0126 0.543 (0.336-
0.878) 
Male 88 (33) 27 (52) 63 (30)  Referent 
Age, Mean years 
(range) 
39 (20-71) 38 (24-71) 40 (20-63) 0.147  
Age, Median years 38 36 39 0.087  
18-24 6 (2) 0 (0) 6 (3)   
25-44 178 (68) 42 (81) 136 (64)   
45-64 76 (29) 8 (15) 68 (32)   
>65+ 1 (0) 1 (2) 0 (0)   
HIV PositiveA 263 (100) 52 (100) 211 (100)   
CD4 cells/mm3 B      
Mean CD4 (range) 271 (3-1464) 199 (7-829) 291 (3-1464) 0.0061  
Median CD4  219 140 242 0.0004  
<200 103 (39) 31 (60) 72 (34)   
201-350 64 (24) 9 (17) 55 (26)   
351-500 27 (10) 4 (8) 23 (11)   
>500 31 (12) 4 (8) 27 (13)   
Unknown 38 (14) 4 (8) 34 (16)   
On ARVSs      
Yes 135 (51) 17 (33)  118 (56)  0.003 0.46 (0.272-
0.780) 
No 128 (49) 35 (67) 93 (44)  Referent 
Median days on 
ARVs (range) 
407 (6-2393) 49 (14-811) 488 (6-2393) 0.0011  
Duration on ARVs      
On ARVs <90 days 23/135 (17) 7/17 (41) 16/118 (13)   Referent 
On ARVs >90days 75/135 (56) 4/17 (23) 71/118 (60) 0.0008 0.1752 (0.056-
0.546) 
Unknown 37/135 (27)  6/17 (35) 31/118 (26)   
Why At Clinic      
To See Doctor 74/175 (42) 15/32 (47)  59/143 (41) 0.561 1.136 (0.748-
1.724) 
Not to see Doctor 101/175 (58) 17/32 (53) 84/143 (59)  Referent 
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The median number of days on ARV treatment was 49 days for the TB cases and 488 
days for the non-TB cases (p=0.0011). Of the 135 patients on ARVs, more patients in the 
TB group had been on ARV therapy for less than 3 months compared to the non-TB 
group (41% vs. 13% respectively). The difference between the two groups was 
statistically significant (p=0.0008, RR for patients on ARVs >90days: 0.1752, 95% CI 
(0.056-0.546)). Of the 128 patients not on ARVs, 69 (54%) had CD4 counts less than 200 
and were eligible to receive ARVs.  
 
Patients were also asked why they had presented to the ARV clinic on the day of 
enrollment, although this information was only available for 175/263 enrolled patients. 
More than ½ of all patients (58%) were attending clinic for collection of monthly pill 
supply or for blood draws and of the 42% who had come to see the physician, almost 
30% were presenting for initiation of ARVs. 17/32 patients (53%) who were diagnosed 
with TB were not going to see the physician on the day of enrollment. The rate was 
similar among non-TB cases, of whom 84/143 (59%) were also not going to see a 
physician, with no statistically significant difference between the two groups (p=0.561).  
 
TB Symptoms and Risk Factors:  
All patients, irrespective of TB status, reported high rates of TB symptoms as 













Risk (95% CI) 
Cough      
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Yes 252 (96) 50 (96) 202 (96) 0.892 1.091 (0.304-3.917) 
No 11 (4) 2 (4) 9 (4)  Referent 
Fever      
Yes 202 (77) 45 (87) 157 (74) 0.063 1.94 (0.923-4.081) 
No 61 (23) 7 (13) 54 (26)  Referent 
Night Sweats      
Yes 206 (78) 41 (79) 165 (78) 0.919 1.031 (0.567-1.874) 
No 57 (22) 11 (21) 46 (22)  Referent 
Weight Loss      
Yes 215 (82) 48 (92) 167 (79) 0.028 2.679 (1.015-7.073) 
No 48 (18) 4 (8) 44 (21)   
Chest Pain      
Yes 204 (78) 39 (75) 165 (78) 0.6204 0.868 (0.497-1.514) 
No 59 (22) 13 (25) 46 (22)   
TB Contact      
Yes 65 (25) 8 (15) 57 (27) 0.0816 0.554 (0.275-1.115) 
No 198 (75) 44 (85) 154 (73)  Referent 
Contact Same House      
Yes 44/65 (68)  6/8 (75) 38/57 (67) 0.684 1.364 (0.301-6.176) 
No 20/65 (31) 2/8 (25) 18/57 (32)  Referent 
Prison      
Yes 6 (2) 4 (8) 2 (1) 0.004 3.569 (1.919-6.640) 
No 257 (98) 48 (92) 209 (99)  Referent 
Mine2Yrs      
Yes 2 (1) 1 (2) 1 (0) 0.281 2.559 (0.626-
10.456) 
No 261 (99) 51 (98) 210 (100)  Referent 
Prior History of TB      
Yes 111 (42) 15 (29) 96 (46) 0.029 0.555 (0.321-0.960) 
No 152 (58) 37 (71) 115 (55)  Referent 
Hospitalized Past 2 
years 
     
Yes 75 (29) 7 (13) 68 (32) 0.007 0.388 (0.183-0.821) 
No 187 (71) 45 (87) 142 (67)  Referent 
Table 2: TB Symptoms and Risk Factors by TB and non-TB cases 
Almost all patients reported cough (96%), with no statistically significant difference 
(p=0.892) between the TB (96%) and non-TB (96%) cases. The TB-case group had a 
higher reported rate of fever (77%) compared to the non-TB case group (74%) although 
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this difference was not statistically significant (p=0.063). Almost equal numbers of TB 
and non-TB cases reported night sweats (79%, 78%) and chest pain (75%, 78%), with no 
statistical difference between the two groups (p=0.919, 0.6204). Weight loss was the only 
TB symptom that differed between the two groups and was statistically significant 
(p=0.028). 92% of all TB cases self-reported weight loss, compared to only 79% of non-
TB cases.   
 
Common TB risk factors were also assessed, as described in Table 2. Paradoxically, 
more non-TB cases than TB cases reported having a current TB-positive contact (27% 
and 15%, respectively), although the difference between the groups was not statistically 
significant (p=0.0816). Most patients (68%) who reported having a TB contact also lived 
in the same house with the contact, with no significant difference between the TB and 
non-TB case groups (75%, 67%, p=0.684). Despite only 6 patients having been 
incarcerated in the past two years, the difference in incarceration rates between TB and 
non-TB cases was statistically significant (p=0.004; RR: 3.569, 95%CI (1.919-6.640)). 
Only 2 individuals had worked in a mine in the past two years, and there was no 
statistical difference in rates of mine exposure between the TB and non-TB groups (2%, 
0% respectively, p=0.281). 42% of all patients reported a prior history of TB. Patients 
found to have TB reported lower rates of prior TB than patients who did not have TB 
(29% and 46% respectively). This difference was statistically significant (p=0.029, RR: 
0.555, 95%CI (0.321-0.960)). 29% of all patients also reported being hospitalized within 
the past two years, with 13% of TB-cases reporting hospitalization compared to 32% of 
non-TB cases. Thus non-TB cases were more likely to have a history of hospitalization 
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and this difference was statistically significant (p=0.007, RR: 0.388, 95%CI (0.183-
0.821)).   
   
Socioeconomic Characteristics:  
Socioeconomic characteristics of the study sample, grouped according to TB status are 












Employed      
Yes 21 (8) 7  (13) 14 (7)  0.111 1.77 (0.915-
3.424) 
No 239 (91) 45 (87) 194 (92)  Referent 
Attended School, Ever      
Yes 144 (55) 30 (58) 114 (54) 0.635 1.127 (0.688-
1.846) 
No 119 (45) 22 (42) 97 (46)  Referent 
Level attained       
High School or higher 75/144 (52) 16/30 (53) 59/114 (52)  0.9130 1.036 (0.548-
1.960) 
Primary School 69/144 (48) 14/30 (47) 54/114 (47)  Referent 
Electricity      
Yes 41 (16)  7 (13) 34 (16) 0.637 0.842 (0.408-
1.737) 
No 217 (83) 44 (85) 173 (82)  Referent 










Unknown 3 (1) 1 (2) 2 (1)   
Water Sources      
Surface Water 119 (45) 25 (48) 94 (45)   
Piped Water in Home 66 (25) 14 (27) 52 (25)   
Communal Tap 78 (30) 13 (25) 65 (31)   
Cooking Facilities      
Wood 196 (75) 40 (77) 156 (74)   
Paraffin 37 (14) 8 (15) 29 (14)   
Gas 14 (5) 1 (2) 13 (6)   
Electric 16 (6) 3 (6) 13 (6)   
Unknown 0 (0) 0 (0) 0 (0)   
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Income      
Mean Household 






841 (0-3000) 0.812  
Median Household 
Income/month in ZAR  
800 800 800 0.639  
Median # Household 
members (range)  
6 (0-26) 8 (0-17) 6 (0-26) 0.0232  
Table 3: Socioeconomic indicators by TB and non-TB cases 
These data indicate that the overall population seen in the ARV clinic, irrespective of TB 
status, is impoverished. Only 8% of all patients reported being currently employed, with 
no significant difference between the TB and non-TB case groups (13%, 7% respectively, 
p=0.111). Overall, 55% of patients reported having ever attended school, and of those ½ 
had completed high school or greater, while the other ½ had only completed primary 
school. Education rates were similar between the TB and non-TB groups (58%, 54%, 
p=0.635). Living conditions were poor among all patients enrolled in the study. Only 
16% of patients had electricity in their homes and 99% lacked proper sanitation, using a 
non-flushing outdoor toilet. 45% of patients’ used surface water such as local ponds and 
rivers as their daily water source, although 30% reported having access to a communal 
tap and 25% had piped water in their homes. The majority of patients used wood stoves 
for cooking (75%), although some did report having paraffin stoves (14%), gas stoves 
(5%) and electric stoves (6%). Rates of employment, education, electricity in the home, 
and types of sanitation, water sources, and cooking facilities were similar between the TB 
and non-TB groups. The mean household monthly income for patients was 834 ZAR 
(range: 0-3000 ZAR), approximately US $81.90, with a median household size of 6 
individuals (range: 0-26). Although the mean household incomes for the TB and non-TB 
case groups were similar (811 ZAR, 841 ZAR, p=0.812), the TB-case group had a larger 
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median number of household members (8 persons) compared to the non-TB case group 
(6 persons). This difference was statistically significant (p=0.0232).  The median 
household income for both groups was 800 ZAR.  
 
Delayed Diagnosis: 
TB Prevalence and Demographics 
To address the issue of delayed diagnosis of TB, inpatient and outpatient populations of 
TB suspects were combined. 480 patients were enrolled from inpatient and outpatient 
settings between February 1, 2008 and August 31, 2008. Of these, 122/480 (25.4%) 
patients were determined to be “TB cases” and 358 were determined to be “non-TB 
cases.” 89% of all TB cases were in HIV-positive individuals. 68/122 (56%) TB-cases 
were smear-positive for AFB on sputum microscopy and/or concentrated fluoroscopy at 
the reference laboratory. Of the 68 smear-positive cases, only 6 (9%) were smear-positive 
for AFB at the COSH laboratory. DST results were available for 100/122 TB cases, of 
which 76 (76%) met criteria for drug-susceptible TB and 24 (24%) for drug-resistant TB, 
of which 8 (8%) were MDR-TB and 16 (16%) XDR-TB.  
 
Of the 122 TB cases, 52 (43%) were identified from the ARV clinic, 7 (6%) from the 
outpatient department, 40 (32%) from the male and female medical wards, and 23 (19%) 
from the male and female TB wards. Of the 66 patients with TB symptoms enrolled from 
the female medical ward, 20 (30%) were found to be TB-positive, and 20/48 (42%) 
patients enrolled from the male medical ward were found to be TB positive. 6/8 patients 
(80%) diagnosed with MDR-TB were enrolled from the ARV clinic and 2/8 (20%) from 
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the general male TB ward. 7/16 patients (44%) diagnosed with XDR-TB were enrolled 
from the ARV clinic, 3/16 (19%) from the male and female medical wards, 1/16 (6%) 
from the female TB ward, and 5/16 (31%) from the male TB ward.  
 
Characteristics Associated with Delayed Diagnosis:  
Analysis of characteristics associated with delayed diagnosis was restricted to 474/480  
 
patients for whom information regarding duration of symptoms prior to clinical  
 
evaluation was available. Of these 474 patients, 344 (73%) were evaluated within four  
 
weeks of onset of symptoms. 130 patients (27%) reported onset of symptoms >4 weeks  
 
prior to evaluation and were deemed to have a “delay” in presentation. The distribution of  
 
duration of symptoms prior to evaluation for tuberculosis through active case finding is  
 
depicted in Figure 3. 
 
Figure 3: Duration of patient systems prior to evaluation 
 
The clinical and demographic characteristics of study participants, stratified by “no 
delay” and “delay” are summarized in Table 4. There were a greater proportion of men in 
the delay group (45%) compared to the non-delay group (34%), a difference that was 
statistically significant (p=0.0222, RR for women: 0.711, 95%CI 0.531-0.950). Median 
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age did not significantly differ between the non-delay and delay groups (38.7 years, 40 
years respectively, p=0.0861). HIV status was associated with decreased risk of delayed 
presentation, with 84% of the no-delay group being HIV positive, compared to 70% of 
the delay group. This difference was statistically significant (p=0.0001, RR: 0.441, 
95%CI 0.310-0.628). Although median CD4 count was similar between the two groups 
(187 and 178 for the non-delay and delay groups respectively), whether patients were on 
ARVs or not was associated with delayed presentation. Only 21% of delayed patients 
were on ARVs, compared to 37% of the non-delayed patients (p=0.0007, RR: 0.541, 
95%CI 0.372-0.790). Site of enrollment was not significantly associated with delay, with 
almost equal proportions of patients enrolled from inpatient (31% vs. 39% for non-delay 
and delay groups) and outpatient (69% vs. 61%) settings. Although a greater proportion 
of delayed patients were eventually diagnosed with TB (32%) compared to non-delayed 
patients (23%), this difference failed to reach statistical significance (p=0.0555).  
 
The median household income for this study population was 800 ZAR/month 
(approximately US $79), with a median household size of 6 persons (range: 1-26). 
Although household size was not significantly different between non-delayed and 
delayed groups (6, 5 persons, p=0.6736), delayed patients reported a greater monthly 
income (840 ZAR) compared to non-delayed patients (800 ZAR), a difference that was 
statistically significant (p=0.0316). Patients that had been seen elsewhere were also 
significantly more likely to have delayed presentations (p=0.0034), with 57% of delayed 
patients reporting prior health care encounters for their symptoms compared to 38% of 
non-delayed patients. Most patients were seen at their local clinic (52%), at COSH (19%) 
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or by a private local doctor (27%). Only 1% of patients reported visiting a traditional 
healer prior to presentation. 
 
Table 4: Demographic Characteristics of patients w/ and w/o delayed presentation 
 
Characteristic Total 
N=474  (%) 
No delay 








p-value Bivariate Relative 
Risk (95% CI) 
Sex      
Female 298 (63) 227 (66) 71 (55) 0.0222 0.711 (0.531-0.950) 
Male 176 (37) 117 (34) 59 (45)  Referent 
Median age, years 
(range) 
39.1 38.7 40.0 0.0861  
HIV Status      
Positive 380 (80) 289 (84) 91 (70) 0.0001 0.441 (0.310-0.628) 
Negative 35 (7) 16 (5) 19 (15)  Referent 
Unknown 59 (12) 39 (11) 20 (15)   





On ARVs      
Yes 154 (42) 127 (37) 27 (21) 0.0007 0.541 (0.372-0.790) 
No 318 (67) 215 (63) 103 (79)   
Enrollment Site      
Inpatient 159 (34) 108 (31) 51 (39) 0.1070 1.279 (0.951-1.719) 
Outpatient 315 (67) 236 (69) 79 (61)  Referent 
TB Status      
TB Case 120 (25) 79 (23) 41 (32) 0.0555 1.359 (1.000-1.847) 
Non-TB Case 354 (354) 265 (77) 89 (68)  Referent 
Median household 
size (range) 
6 (1-26) 6 (1-26) 5 (1-26) 0.6736  
Median family 
income (ZAR) 
800 800 840 0.0316  
Median transport 
cost (ZAR) (range) 
30 (0-170) 30 (0-170) 30 (0-130) 0.8120  
Seen Elsewhere 200 (58) 131 (38) 69 (53) 0.0034 1.544 (1.152-2.068) 
Seen Where N=204 N=129 N=175   
Local Clinic 106 (52) 63 (49) 43 (57) 0.0006 1.715 (1.278-2.303) 
COSH 39 (19) 20 (16) 19 (25) 0.0019 1.909 (1.332-2.736) 
Other local doctor 56 (27) 43 (33) 13 (17) 0.4519 0.829(0.502-1.368) 
Traditional Healer 2 (1) 2 (2) 0 (0)   
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Patients provided a variety of responses to the open-ended question “What reasons 
prevented you from coming earlier to be seen for your symptoms?” The most common 
reason cited (by 126 patients, (27%)) was that they did not have sufficient financial 
means for transport or to pay for their hospital chart. Other common responses included 
living too far (36 patients (8%)), feeling too ill to travel to the hospital (9 patients(2%)), 
waiting until they were “critically ill” to be seen (9 patients(2%)), and being required to 
visit the local satellite clinic before a referral was made to COSH (6 patients(1%)). One 
patient reported using traditional medicine first for her symptoms.  
 
Information, Motivation and Behavioral Skills: 
Information 
Patients were relatively knowledgeable about TB disease, its treatment, symptoms, and 
association with HIV disease (see Table 5). 81% of all patients believed that TB is 
treatable and 82% that TB can be cured. Fewer patients were informed about the presence 
of drug-resistant disease, with only 234/480 (49%) of patients reporting that they had 
heard that “some forms of TB are untreatable,” and many (32%) reporting that they 
“didn’t know.” Almost ½ of patients were aware of the association between HIV and TB, 









Table 5: Information about TB amongst TB suspects 
 
When asked to identify symptoms of TB from a list including correct and incorrect 
symptoms of TB, patients generally provided affirmative responses to all symptoms, 
Responses, Total N=480 (%)  
Information Statement: 
Yes No Unknown 
TB is treatable 387 (81) 14 (3) 79 (16) 
TB can be Cured 394 (82) 22 (5) 64 (13) 
Some forms of TB are untreatable 234 (49) 91 (19) 155 (32) 
Having TB means that you have HIV 231 (48) 151 (31) 98 (20) 
HIV is treatable  328 (68) 52 (11) 100 (21) 
Responses, Total N=373 (%)  
The following are symptoms of TB Yes No Unknown 
Chest Pain  277 (74) 30 (8) 66 (18) 
Cough 295 (79) 21 (6) 57 (15) 
Bloody Cough 286 (77) 21 (6) 66 (18) 
Ear Pain 75 (20) 92 (25) 206 (55) 
Fever 264 (71) 31 (8) 78 (21) 
Bacterial Infection 133 (36) 81 (22) 159 (43) 
Memory Loss 159 (43) 77 (21) 137 (37) 
Night Sweats 279 (75) 26 (7) 68 (18) 
Painful Urination 117 (31) 94 (25) 163 (43) 
Stomach Ache 145 (39) 101 (27) 127 (34) 
Swelling 177 (47) 67 (18) 129 (35) 
Tiredness 271 (73) 34 (9) 68 (18) 
Watery Eyes 107 (29) 61 (16) 205 (55) 
Weight Loss 302 (81) 22 (6) 49 (13) 
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although most patients correctly identified cough (79%), chest pain (74%), hemoptysis 
(77%), fever (71%), night sweats (75%) and weight loss (81%) as symptoms of TB. Most 
patients (73%) also believed that tiredness was a symptom of TB. For non-TB symptoms, 
patients generally hesitated to provide a negative response, usually answering 
“unknown.” For example, most patients did not believe that ear pain was a symptom of 
TB (only 20% of patients answered ‘yes’). However, the majority of patients (55%) 
answered “unknown” compared to only 25% who stated that ear pain was not a symptom 
of TB. Many patients incorrectly attributed non-TB symptoms to TB disease, reporting 
that bacterial infections (36%), memory loss (43%), painful urination (31%), stomach 
ache (39%), swelling (47%), and watery eyes (29%) were all symptoms of TB.  
 
Motivation 
We identified a number of barriers that patients face in terms of motivation to seek care 
for their symptoms, summarized in Table 6. The most significant barriers were related to 
socioeconomic factors such as lack of finances for transport and structural barriers such 
as distance to COSH. 55% of all patients reported that they did not have enough money 
for transport to COSH, and 61% believed that they lived too far to access care. Only 8% 
of patients cited their job as a barrier to seeking care, and only 6% were worried about 
loosing their job if they took days off to seek care. However, 31% of respondents stated 
that they could not come to the hospital because of responsibilities at home (e.g. caring 







Responses, Total N=480 (%) Motivation Statement:  
Yes No Unknown 
Socioeconomic/Structural:    
     No money for transport 263 (55) 211 (44) 6 (1) 
     Live too far  294 (61) 181 (38) 5 (1) 
    Working 39 (8) 426 (91) 5 (1) 
    Worried about losing job  29 (6) 435 (91) 16 (3) 
    Responsibilities at home  149 (31) 323 (67) 8 (2) 
Health and Health-system related:     
     Too sick to seek care 248 (52) 224 (47) 8 (2) 
     Willing to stay in the hospital to be treated 268 (56) 192 (40) 20 (4) 
     Have heard that TB rx can make you sick 218 (45) 235 (49) 27 (6) 
     Doctors have been rude in the past 77 (16) 393 (82) 10 (2) 
Perceptions of Stigma and Disease:    
     Worried about being diagnosed with TB 62 (13) 412 (86) 6 (1) 
     Worried about being diagnosed with HIV 65 (14) 406 (85) 9 (2) 
     Can tell family and friends if I have TB 464 (97) 9 (2) 7 (1) 
     Can tell family and friends if I have HIV 424 (88) 43 (9) 13 (3) 
Table 6: Motivation to seek care amongst TB suspects 
 
Patients also endorsed a number of health and health-system related factors related to 
motivation to seek care. 218/480 (45%) patients were aware that TB treatment was 
associated with side-effects, and 192/480 (40%) were unwilling to be hospitalized to 
receive TB treatment. 52% reported that they were too sick to seek care earlier. Most 
patients did not view the health system negatively, with only 16% reporting that doctors 
had been rude in the past.  
 
Most patients did not report high levels of TB and HIV-related stigma, and were willing 
to disclose their status to friends and family. Only 13% of patients cited being worried 
about being diagnosed with TB and 14% with HIV as reasons why they did not seek care 
earlier. 97% of all patients said they would tell their friends and family about TB. In 
comparison, stigma related to HIV appeared to be slightly more prevalent with only 88% 





Patient responses to behavioral skills questions are summarized in Table 7.  
Behavioral Skills Statement:  Responses, Total N=480 (%) 
Where to Seek Care:   
Whom do you usually consult when you are sick?   
     COSH      108 (23) 
     Local Clinic      258 (54) 
     Private local doctor      12 (4) 
     Family member/relative      69 (15) 
     Community elder/chief      11 (4) 
     Sangoma/faith healer      13 (3) 
Do you think that patients should visit COSH for:   
     All illnesses 337 (70) 
     Only for severe illnesses 139 (29) 
Pill-Taking Behavioral Skills:  Yes, n (%) No, n (%) Unknown, n (%) 
Can take pills daily 462 (96) 8 (2) 10 (2) 
Have a place for pills at home 470 (98) 5 (1) 5 (1) 
Have help at home  429 (89) 45 (9) 6 (1) 
Table 7: Behavioral skills related to seeking care amongst TB suspects 
 
With regard to behavioral skills necessary for seeking TB care, most patients identified 
appropriate locations to seek care. 54% reported that they usually seek care at their local 
clinics when ill, and 23% reported they seek care at COSH. 15% of patients reported 
consulting family members, 4% community elders of chiefs, and 3% traditional healers. 
Most patients (70%) believed that they could be seen at COSH for all illnesses, although 
30% believed that they should only visit COSH for severe illnesses. Although patients 
were well informed about where to seek care, few patients knew when to seek care, 
largely due to the misattribution of symptoms to non-TB (and in many cases, non-
medical) causes. Patients self-reported a wide range of causes to explain their symptoms. 
199 patients (42%) said they did not know what was causing their symptoms. 127 
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patients (26%) thought that they had TB. Other common medical causes that patients 
reported included the common cold (34 patients (7%)), the flu (28 patients (6%)) and 
HIV disease (13 patients (3%)). 6 patients (1%) thought they had relapse of prior TB and 
4 patients (1%) believe that they were failing current TB therapy. 4 patients (1%) 
attributed all symptoms to ARV side effects. Preliminary qualitative analysis revealed 
that patients attributed symptoms to a variety of environmental causes such as poor 
working conditions, exposure to coal dust, and cold weather. Patients also provided a 
number of dietary explanations, ranging from poor diet to “drinking too much juice” and 
“eating sour porridge.” Some patients believed that evil spirits were causing their 
symptoms, and one patient attributed his illness to “being poor.”   
 
Almost all patients reported possessing pill-taking behavioral skills, with 96% stating that 
they were able to take pills daily, 98% that they had a location to store pills at home, and 
89% that they had assistance at home to take medication.  
 
Although some IMB questions elicited similar responses from participants (e.g. 
disclosure to family and friends about TB and HIV status), most correlations between 
various IMB items, even when statistically significant, were relatively weak (R<0.2). All 
correlations between the IMB questions are listed in Figure 4. Patients who believed that 
TB is treatable also provided similar responses to the statements, TB can be cured 
(R=0.22, p<0.001), HIV is treatable (R=0.1322, p=0.015), and can you tell your family 
and friends that you have TB (R=0.2002, p<0.001). Patients who reported living too far 
from COSH also stated that they were not willing to be hospitalized for treatment (R= -
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Figure 4: Inter-IMB-question correlations* 
*statistically significant values (p<0.05) highlighted  
 
IMB Response Stratified by Sub-Group 
We performed sub-analyses by stratifying responses to the IMB questionnaire across 
three different populations: 1) patients on ARVs who had received education and training 
regarding opportunistic infections, including TB; 2) patients currently on tuberculosis 
treatment who had also received education regarding TB; and 3) patients who delayed 
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seeking care for >1 month from the onset of symptoms. These responses are compared in 
Figures 5.1-5.3 and Figures 6.1-6.3 depicting the general IMB questions and the TB 
symptom questions, respectively.  
 
Figure 5.1: IMB Results by TB Treatment Status Information 
 
 








Figure 5.3: IMB Results by Delayed Status Motivation 
 
 
Figure 6.1: TB Symptoms by TB Treatment Status* Information 
 
 
Figure 6.2: TB Symptoms by ARV Status* 
*   * 




Figure 6.3: TB Symptoms by Delayed Status* 
*Statistically significant (p<0.05) values indicated by * 
 
Overall, IMB responses for the On TB treatment/Not on TB treatment, On ARVs/Not on 
ARVs, Delayed Presentation/No Delayed Presentation, reflected overall responses as 
described earlier in the results section. However, there were certain questions where 
statistically significant differences were found within the sub-groups. Although almost all 
patients on TB treatment as well as those not on TB treatment believed that TB was 
treatable (95% and 97% respectively, p=0.37), patients on TB treatment were 
significantly less likely to believe that TB could be cured compared to patients not on TB 
treatment (89%, 96% respectively, p=0.022, see Figure 5.1). Patients on ARVs were 
more likely to associate TB with HIV (71%) compared to patients not on ARVs (55%). 
This difference was statistically significant (p=0.002). Patients on ARVs also were less 
likely to live far away compared to patients not on ARVs (53%, 66%, p=0.006, see 
Figure 5.2).    
 
Knowledge about TB symptoms across all three sub-populations also reflected general 




as well as many affirmative responses for non-TB symptoms. Overall, patients on ARVs 
tended to attribute non-TB symptoms (such as ear pain, swelling, watery eyes, etc.) to TB 
more often than any other group. There were no statistically significant differences about 
knowledge about TB symptoms between patients on TB treatment and patients not on TB 
treatment. Patients who were on ARVs were significantly more likely to identify cough, 
bloody cough, fever and night sweats as TB symptoms compared to patients not on 

































We performed a prevalence study of active undiagnosed tuberculosis among HIV-
positive individuals attending an ambulatory ARV clinic at a local district hospital in 
rural South Africa. A number of findings from this study may be useful in efforts to 
strengthen TB programs in high HIV-prevalence settings.  Four important findings 
emerged from this study.  The first and most salient finding was the high rate of 
undiagnosed tuberculosis among this ambulatory ARV clinic patient population. We 
found that twenty percent of  “TB suspects,” identified by a simple symptom screen, were 
sputum culture positive for M. tuberculosis.  In addition, 24/52 (46%) TB cases were 
smear positive, well known to be associated with increased likelihood of TB 
transmission. Furthermore, 5% of all enrollees attending the ARV clinic had sputum 
culture-confirmed multidrug-resistant TB, resistant to at least isoniazid and rifampin, and 
3% meeting criteria for XDR-TB. A second finding from this study is the identification 
of several risk factors for active TB in this population. Third, Using the IMB model of 
patient behavior, and classifying patients as to whether they had “delayed diagnosis” or 
not, we also identified several important barriers to accessing care. We found that 27% of 
all enrolled patients had had symptoms for >4 weeks prior to enrollment and were 
considered “delayed diagnosis” and that the most salient barriers to care were 
socioeconomic factors in the very poor patient population that comprised our study.  
 
In addition to patients in the ARV clinic, we also surveyed and documented high rates of 
active TB among hospitalized patients. Particularly concerning were our findings that 
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42% and 30% of all symptomatic patients from the male and female medical wards, 
respectively, were later found to have culture-confirmed TB, including 3 patients with 
XDR-TB.  A previous prevalence study in 2006 among inpatients and outpatients at our 
study site in Tugela Ferry reported high rates of MDR-TB (39% of all patients with 
cultured-confirmed TB) and XDR-TB (6% of all patients with culture-confirmed TB) 
[15]. Since that time, there has been a greater integration of TB and HIV services, 
improved infection control measures, and increased use of culture in order to promptly 
diagnose and treat drug-resistant tuberculosis cases. Given these changes, we were 
interested in determining updated prevalence rates of TB and drug-resistant TB among 
this population. 
  
In these studies, sputum smears were done at two sites, the referral laboratory where 
culture and DST was done, and the local laboratory at the district hospital where the 
study was conducted. At both institutions, sputum smear sensitivity was low, 46% at the 
referral laboratory and a significantly lower rate of 8% at the local hospital.  
 
High Rates of Undiagnosed TB 
The high rates of TB and drug-resistant TB in the ARV clinic are noteworthy and 
disturbing. Our findings are consistent with prior reports documenting higher prevalence 
rates of XDR-TB than MDR-TB in this setting [79]. Previous studies have also shown 
high rates of TB in areas of high-HIV prevalence [69-72], although many of these studies 
did not restrict enrollment to symptomatic patients and none evaluated outpatient ARV 
clinic settings. These studies reported prevalence rates as high as 10% among all HIV 
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patients, whereas our study prevalence is restricted to symptomatic patients. More than 
50% of the TB cases had smear-negative TB, and >50% of patients diagnosed with TB 
were presenting to the clinic for treatment collection (and were not going to see a 
physician). It is thus very likely that many of these patients would not have been 
diagnosed with TB without our active case detection and TB screening strategy of 
performing culture and DST on all TB suspects. Given the increased mortality from drug-
susceptible and drug-resistant TB among HIV patients, our study findings support the use 
of active case detection among HIV-positive individuals as advocated by the WHO [71]. 
This is even more compelling in settings where high rates of drug resistant TB are known 
to be present.  
 
Such findings support prior observations that nosocomial transmission is an important 
driver of the MDR and XDR-TB epidemics in this region[12, 15, 80] These findings 
underscore the great need for infection control measures in both ambulatory and inpatient 
settings with high rates of drug-resistant TB and HIV [21, 81, 82] to protect not only 
immunocompromised patients at greater risk [4] but also health care workers. As Basu 
and colleagues demonstrated in their mathematical model, 28% of XDR-TB cases in 
Tugela Ferry could be averted over 5 years simply with the use of N-95 respirator masks 
and reducing length of hospital stays. If this setting also adopted rapid DST techniques, 
isolated patients into clusters of five, improved natural ventilation, and scaled up HIV 
testing and treatment programs, it could avert up to 48% of all XDR-TB cases over five 
years [21]. In addition, transmission of drug-susceptible and drug-resistant TB to 
healthcare workers is of extreme concern given the severe shortages of trained healthcare 
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workers in rural areas in South Africa. The deaths of numerous staff members who have 
acquired drug-resistant TB have led many others to seek new positions, and have posed 
significant challenges in finding personnel willing to work in such a high-risk area. HIV-
positive health care workers are at particularly increased risk. At COSH, all staff 
members are provided with confidential VCT for HIV and treatment as appropriate, as 
well as the option of switching to a less high-risk area. The same mathematical model 
predicted that consistent use of respirator masks and VCT could avert 75% of staff cases 
of XDR-TB [21]. 
 
Culture and DST results were not available for 6-8 weeks after sputum was obtained in 
our study, and were not able to guide clinical care or admission policies for TB patients. 
Since there are no individual patient isolation rooms available in this resource-
constrained setting, the development of rapid TB diagnostics tests would also aid in 
appropriately identifying drug-susceptible and drug-resistant TB prior to these patients 
being admitted to general medical wards. Until these rapid tests are available however, 
culture and DST remains the only means by which to diagnose MDR and XDR-TB. In 
our study, 28% of all available DST results revealed MDR or XDR-TB. WHO and South 
African Department of Health guidelines do not advocate for the routine use of sputum 
culture for diagnose of TB, reserving it for groups at “high-risk” for drug-resistant TB [3, 
64]. Unfortunately, identification of those at “high risk” is imperfect and often fails to 
capture patients who have primary drug-resistant TB. The poor sensitivity of sputum 
microscopy in HIV-positive patients who frequently have paucibacillary disease, as well 
as high prevalence rates of MDR and XDR-TB documented in this study and others 
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provide support for expanding the use of both sputum culture and DST as an essential 
component of TB diagnosis.   
 
Risk Factors for TB  
Patients in our study were more likely to have TB if they were male, had lower median 
CD4 counts and were not on ARVs. Patients who were on ARVs had a relative risk of 
0.46 of having TB, and patients who were on ARVs for more than 90 days had a relative 
risk of 0.175 of having TB compared to patients who were not on ARVs or on ARVs for 
<90 days, respectively. Although HIV-positive patients on ARV therapy still have an 
increased chance of developing active TB compared to HIV-negative patients [83], ARV 
therapy has been shown to reduce HIV-positive patients’ risk of TB [84]. Furthermore, 
previous studies have shown that integrating TB and HIV treatment can improve patient 
outcomes and rates of adherence [85]. These results are consistent with such studies, and 
highlight the need for better integration of TB-HIV services, and prompt initiation of 
ARV therapy in all HIV-TB co-infected patients. Our finding that ½ of patients who were 
eligible to receive ARVs (based on CD4 count) were on ARVs indicates better ARV 
coverage rates than the national average of 28% [2], but demonstrates the need for 
strengthening not just TB programs, but HIV treatment infrastructure as well so that all 
patients eligible for ARVs actually receive them. Although socioeconomic factors were 
not associated with TB status in our study, the high rates of unemployment, low income, 





In our study, patients who had been hospitalized within the past two years or had a prior 
history of TB were less likely to have active TB at the time of enrollment. We suspect 
that such findings may be partially a result of selection bias, in that non-TB patients had 
higher rates of prior TB, and were likely hospitalized for these previous episodes of TB. 
Also, patients who were currently on TB therapy were excluded from our study. 
Therefore, patients who had been hospitalized and diagnosed with TB during their 
admission had been receiving treatment at the time of enrollment (and were ineligible for 
our study) or had completed treatment (and were symptom-free and did not meet 
eligibility criteria).  
 
We also documented high prevalence rates of TB symptoms among all patients in our 
study, irrespective of TB status. Although prior studies have found that a combination of 
symptom screening, chest x-ray, and sputum microscopy can have a sensitivity of greater 
than 80% in diagnosing active TB [86], in our study, except for weight loss, there was no 
significant difference between patients with and without TB in terms of symptoms. Our 
study design did not include follow-up of TB culture-negative patients, and it is possible 
that some of these “TB-negative” patients had active pulmonary or extrapulmonary TB 
that was not detected by sputum culture. Without clinical follow-up, it is also unclear 
what other pathology might explain to the high prevalence of TB symptoms in non-TB 
culture positive patients in this population.  In addition, prior studies have documented 
atypical TB symptoms in HIV-infected patients, including completely asymptomatic 
patients who are TB culture positive [69, 72, 86], suggesting the use of culture to 





In order to better understand these findings, we also performed a study characterizing 
barriers to seeking care for TB symptoms and factors associated with delayed diagnosis 
for inpatients and outpatients seeking care at COSH. Characteristics associated with 
delayed presentation included male gender, not HIV-positive or not on ARVs, and having 
been seen elsewhere prior to enrollment. Although patients were generally 
knowledgeable about TB, did not report high rates of HIV and TB-related stigma, and 
were well informed about where to seek care, many patients misattributed the cause of 
their disease or were unaware when they should consult a physician for their symptoms. 
In addition, most patients reported that they lived too far and did not have enough money 
for transport and hospital fees to seek care. Many of the previously described TB and 
HIV policy changes at COSH have addressed health-system barriers to diagnosis and 
treatment of TB and prevention of TB transmission. Fewer policy changes have focused 
on patient-related barriers and causes for delay. Although there is a large body of 
literature characterizing causes of patient delay in seeking care for TB symptoms, it is 
clear that many of these causes vary from location to location [23]. Although some 
factors affecting patient delay have been characterized for a rural province in northern 
South Africa [30], barriers may vary widely between provinces local health systems, 
particularly given different rates of HIV, local health perceptions, and quality of health 
services. Factors affecting patient delay in Tugela Ferry have not been thoroughly 
characterized, and it is unclear what interventions may reduce patient delay.  We thus 




We found that 27% of our patients delayed seeking care for 4 weeks or more from the 
onset of TB symptoms. Since our study design was based upon active case detection of 
TB, we likely aborted the natural duration of delay that would have occurred without our 
intervention (see further discussion in Limitations, below). HIV-positive patients and 
those on ARVs were less likely to be delayed in our study, consistent with previous 
findings in Thailand [87], as a result of their engagement with the health care system and 
ARV clinic, which requires all patients to return to the clinic monthly for treatment 
collection. Although prior studies have shown limited TB knowledge to prolong patient 
delay, in our study, degree of delay was not significantly associated with level of patient 
knowledge about TB but as discussed in the Limitations section, our definition of delay 
and study design may not have been able to detect such associations.    
 
Using the IMB model of patient behavior, we identified several important barriers to 
accessing care, the most salient being socioeconomic factors. Overall, our patients were 
very well informed about TB, its treatment, and its symptoms. Some interesting 
differences were found in terms of knowledge about TB symptoms across various sub-
groups. Patients who were on ARVs, and had undergone educational training sessions 
about HIV treatment, side effects and opportunistic infections (including TB) identified 
cough, bloody cough, fever and night sweats as TB symptoms significantly more than 
patients not on ARVs (who had not received the training). This suggests that patient 
education, particularly about TB and its symptoms is beneficial. That there was no 
difference between the patients currently on TB treatment and those not on TB treatment 
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in terms of TB symptom knowledge is disappointing, and perhaps indicates the need for 
strengthening TB patient education through the provincial TB program.  
 
With regards to motivation, our patient population did not identify community stigma 
about TB and HIV as a barrier to seeking care, unlike some settings where stigma was a 
major deterrent for patients [42]. Our study also revealed positive patient perceptions 
about the health care system, with most patients attending local satellite clinics or COSH 
for medical care. Few patients in our study sample utilized traditional healers and 
medicines, in contrast to prior studies in similar settings [46, 47], although this may be 
due to patient reluctance to disclose the use of traditional medicines in a hospital setting 
(see discussion in Limitations, below). Further work needs to be done to evaluate the 
impact of traditional medicines on patient delay in this setting.  
 
In our study, most patients identified lack of money for transport and hospital fees, and 
distance from clinics/COSH as the biggest barriers to seeking care. Both distance to 
health care and lack of money have been frequently cited as barriers to care, especially 
among rural populations [24, 26, 28, 29, 31, 33, 45]. TB programs could consider 
addressing such barriers by providing community-based TB screening and treatment, as 
well as transportation to the hospital.  
 
With regards to behavioral skills, most of our patient population was about to identify 
where they should access care. Unlike settings where patients utilize private pharmacies 
and physicians [28, 32, 33, 45, 49, 51], our findings are more consistent with previous 
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studies in rural South Africa [30] in that most patients utilize public clinics and hospitals 
for care. Patients were less informed about the cause of their symptoms and when to seek 
care. Although many of our patients attributed their symptoms to TB disease, and some 
even to TB treatment failure, many patients identified non-biomedical causes of their 
symptoms such as environmental factors, spirits, and food. Such misattributions are 
consistent with prior studies [41, 46, 48, 51, 52]. Providing all HIV-positive patients with 
clear guidelines regarding when to seek medical care may reduce such patient delay.  
 
Limitations 
There were several important limitations to this study. First, we only enrolled patients 
who had cough or two or more TB symptoms in this study. We also excluded patients 
who were unable to produce sputum. Given the higher rates of extrapulmonary TB and 
often atypical TB presentations in HIV-positive patients, we likely missed patients who 
had active extrapulmonary TB or pulmonary TB without classic TB symptoms. Secondly, 
although liquid culture methods are considered the gold standard for TB diagnosis, they 
do not have 100% sensitivity for TB, especially in operational settings, as evidenced by 
the several patients who were sputum-smear positive but culture negative. False negatives 
can be attributed to inherent limitations in the culture methodology, as well as inadequate 
sputum sampling, poor refrigeration, and duration of transport. Therefore, it is possible 
that there were smear-negative TB patients with false-negative cultures that we failed to 
diagnose in this study. The true prevalence of active TB among this population would 
have likely been higher had we not restricted enrollment to symptomatic patients and if 
we had clinically followed patients with negative TB-cultures to ensure that they were 
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truly TB-negative. The cumulative effect of these limitations is that the rates of 
unrecognized active TB that we have reported in the TB screening study are minimum 
estimates. Our conclusion that there is a high rate of undiagnosed TB in the ARV clinic is 
not compromised by these limitations. In addition, DST performed by the 1% proportion 
method has a 1-3% error rate in most laboratories resulting in both false positives and 
negatives. As such, errors in DST as well as lack of DST for patients whose samples were 
repeatedly contaminated could affect the stated MDR and XDR-prevalence rates, 
although quality control procedures attempt to avoid this.      
 
With regard to the delayed diagnosis study, given that we were conducting active case 
detection for all enrolled patients, we likely aborted any further delay in diagnosis for 
enrolled patients, i.e. it is possible that were these patients not enrolled in the study they 
would not have been diagnosed with TB for several additional weeks or months, if at all. 
Therefore, the “delayed diagnosis” category, and resulting findings likely underestimate 
the true degree of delay amongst this patient population. In addition, it is possible that 
many of associations between patient delay and various risk factors that were non-
significant in this study might have been statistically significant had we truly waited for 
patients to self-present through passive case detection as is current COSH protocol. We 
also suspect that we received biased answers to certain questions, particularly those 
involving traditional healers, given that health care providers were asking the questions 
within a medical setting. Previous studies in rural South Africa have documented high 
percentages of patients using traditional medicine and visiting sangomas or faith healers 
for TB symptoms [47]. Anecdotal evidence from health care providers in Tugela Ferry 
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also supports this finding, but patients are often reluctant to disclose their use of 
traditional medicine in Western medical settings. Therefore, although local health care 
providers often find evidence that patients have visited traditional healers, patients will 
rarely share this information. Therefore, we have likely underestimated the degree to 
which patients utilize traditional medicines and healers, and their impact on patient delay. 
Despite these limitations, we believe that this study is one of the first characterizing 
barriers to TB diagnosis in areas of high HIV and MDR/XDR-TB prevalence, and 
contributes to the existing literature on prevalence rates of MDR and XDR-TB in this 
region.   
  
Conclusions and Implications 
The results of this study re-affirm alarming prevalence rates of active TB, and 
particularly MDR and XDR-TB among HIV-positive patients in rural South Africa. In 
addition, and of great concern, is that these findings were derived from a congregate 
health care setting with either all or most patients being HIV-positive and therefore put at 
risk for transmission of drug-sensitive and drug-resistant TB as they access care services. 
Although a number of studies have evaluated TB among HIV-positive patients in 
antenatal and TB clinics, and VCT centers, to our knowledge, this is the first study 
evaluating TB prevalence among an entirely HIV-positive clinic population. In addition, 
our study also identifies a number of barriers to TB diagnosis including poor sensitivity 
of smear microscopy and high prevalence of TB symptoms in non-TB patients, as well as 




As tuberculosis continues to be the leading cause of mortality among HIV-positive 
patients worldwide, and rates of MDR and XDR-TB increase, it is clear that a 
multifaceted approach is required to confront  these challenges. Given the limited 
efficacy,  great cost, , and toxic side effects of MDR and XDR-B treatment, greater 
efforts need to be made to prevent drug-resistant cases. Infection control must become a 
priority to avoid not only nosocomial transmission to patients, but to avert further loss of 
healthcare workers, who are already in great demand and short supply. Moreover, earlier 
case detection using active TB case finding and expanded use of sputum culture and DST 
are essential to preventing nosocomial and community-based TB transmission and 
improving patient outcomes. However, given limitations in laboratory infrastructure and 
human resources, it is unlikely that sputum culture and DST will be made available to all 
TB suspects in the near future. Future research must be done in areas of high HIV and 
drug-resistant tuberculosis to develop sensitive and specific clinical algorithms to identify 
TB patients prior to the availability of results of cultures and DST and without the use of 
culture. Concomitantly, rapid diagnostic techniques that are inexpensive, rapid, and easily 
performed in peripheral settings are direly needed. Greater efforts also need to be made to 
educate patients, particularly TB, HIV and TB/HIV co-infected patients on the signs and 
symptoms of TB, and when to seek medical care for symptoms. Community-based 
education and TB screening would remove many of the barriers that patients report in 
seeking care. Further research needs to be done in evaluating such programs and 
measuring their impact on TB outcomes.  Taken together, all of these needed strategies 
could be effective in reducing the spread and adverse consequences of drug susceptible 
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APPENDIX A: Patient Enrollment Forms 
General Patient Interview Form 
 
Site of enrollment: (e.g. ARV, OPD, Inpatient, FTB, MTB):____________________________ 
Instructions: The questions are to be read to the patient in their native language 
1. Sex of patient? (circle one) Male         Female 
INCLUSION / EXCLUSION CRITERIA 
2. What is your date of birth? (yyyy/mm/dd); if unknown please record 
age below  
3. What is your age? (write in years)   
If the patient is <18 then patient is not eligible for the study.  STOP 
4. Are you currently taking any anti-tuberculosis therapy? (circle one; if 
unknown, please record as many details as possible; If no, continue to 
Question # 7) 
 
Yes           No 
 
5. If yes, for how long? (write in number of days, weeks or months)  
If patient is on TB treatment, look at the patient’s green card (if available, if not, ask patient for 
details)   
Date of TB treatment start (dd/mmm/yyyy), record from green card:  ______ / __ ___ __ / __ __ ___ _ 
Record TB regimen patient is taking, using green card. (write in 
space)  
Record TB registration status (new, re-treatment, etc.), using green 
card. (write in space)  
If on TB treatment for more than 48 hours but less than 2 months then patient is not eligible for the 
study. STOP. 
 
If less than 48 hours on TB treatment, then continue to Question 7.   
If more than 2 months on TB treatment, then continue to Question 6. 
6. Do you still have symptoms of TB (e.g., cough, fever, night sweats) 
after 2 months of TB treatment?  Yes           No 
If yes, then continue to Question #7. 
If no, patient is not eligible for the study, STOP. 
7.  Are you taking any other medications? (circle one) Yes           No 
       7a. If yes, list the other medications taken by the patient  
If the patient is taking ciprofloxacin, ofloxacin, amikacin, or streptomycin, the patient is not eligible 
for the screening program.  STOP. 
READ PATIENT CONSENT FORM AND HIPAA FORM (IN ZULU OR ENGLISH) and have patient sign. 
8. Did the patient consent to be in evaluation? (circle one) Yes           No 
If “no”, then please record why patient has declined participation in the study:__________________ 
_____________________________________________________________________________________ 
 
If patient is eligible for study, continue with Page 2. 





  9. Do you have a cough right now? (circle one) (If no, skip to 
question #13) Yes      No     Unknown 
10. If yes, how many weeks have you been coughing? (write in # of 
weeks)  
11. Is your cough productive?  (circle one) Yes      No     Unknown 
12. Have you been coughing up blood? (circle one) Yes      No     Unknown 
In the 2 months before coming to the hospital/clinic what symptoms have you been having? 
13. Fever? (circle one) Yes      No     Unknown 
14. Weight loss? (circle one) Yes      No     Unknown 
15. Night sweats? (circle one) Yes      No     Unknown 
16. Shortness of breath? (circle one) Yes      No     Unknown 
17. Chest pain? (circle one) Yes      No     Unknown 
18. Diarrhea? (circle one) Yes      No     Unknown 
19. Loss of appetite? (circle one) Yes      No     Unknown 
20. Fatigue? (circle one) Yes      No     Unknown 
PAST TUBERCULOSIS EXPOSURE 
21. Do you live with, or have you been in contact with someone who 
you think may have TB or is being treated for TB? (circle one)  Yes      No     Unknown 
          22a. If yes, is this person living in the same household as you?  
                      (circle one) Yes      No     Unknown 
22. Have you been in prison in the past 2 years (circle one) Yes      No     Unknown 
23. Have you worked in a mine in the past 2 years? (circle one) Yes      No     Unknown 
          23a. If yes, do you work in a mine now? (circle one) Yes      No     Unknown 
PAST TB HISTORY 
24. In the past, have you ever been told by a nurse or doctor that you 
have TB? (circle one)     If no, skip to question #25 Yes      No     Unknown 
*If yes, may need to consult with TB program office for details of past treatment and outcomes. 
          24a. If yes, how many times have you had TB before? (write in 
answer)  
          24b. If yes, when did you last have TB? (write in date)  
          24c. If yes, have you ever been seen or admitted to King 
George V Hospital? (circle one) Yes      No     Unknown 
          24d. If yes, what was the outcome of TB treatment? (circle one)  
         (Please get this result from the TB DOT office only, not from 
patient) 
Cure      
Treatment Completion   




*If patient has OPD folder, look for COSH admission sheets for admissions and dates in past 2 
years. 
25. Has the patient been hospitalized for ANY reason in the past 2 
years? (circle one)  If no, skip to #26 Yes      No     Unknown 
         25a. If yes, number of prior hospitalizations in past 2 years (write 
in number)  





VIEWS ON TB 
26. Please answer yes or no to the following statements based on what you think:  
  26a. Do you think that TB is treatable? (circle one) Yes      No     Unknown 
  26b. Do you think that TB can be cured? (circle one) Yes      No     Unknown 
  26c. Do you think that that some forms of TB can’t be treated? (circle 
one) Yes      No     Unknown 
  26d. Do you think having TB means that you have HIV? (circle one) Yes      No     Unknown 
  26e. Do you think that HIV can be treated? (circle one) Yes      No     Unknown 
  26f. Can you tell your family if you have TB? (circle one) Yes      No     Unknown 
  26g. Can you tell your family if you have HIV? (circle one) Yes      No     Unknown 
  26h. Are you willilng to stay in the hospital to be treated if you have 
TB? (circle one) Yes      No     Unknown 
  26i.Do you live too far away to be treated? (circle one) Yes      No     Unknown 
  26j. Do you have money to get to the hospital to be treated? (circle 
one) Yes      No     Unknown 
  26k. Have you heard that pills for TB can make you sick? (circle one) Yes      No     Unknown 
  26l. Can you take pills every day? (circle one) Yes      No     Unknown 
  26m.Do you have a place to keep your pills at home? (circle one) Yes      No     Unknown 
  26n. Is there someone at home to help you take your pills? (circle 
one) Yes      No     Unknown 
27. Are the following symptoms of TB?  
  27a. Chest pain  Yes      No     Unknown 
  27b. Coughing for longer than two weeks Yes      No     Unknown 
  27c. Coughing up blood Yes      No     Unknown 
  27d. Ear pain Yes      No     Unknown 
  27e. Fever Yes      No     Unknown 
  27f. Many bacterial infections Yes      No     Unknown 
  27g. Memory loss Yes      No     Unknown 
  27h. Night sweats Yes      No     Unknown 
  27i. Pain with urination Yes      No     Unknown 
  27j. Stomach ache Yes      No     Unknown 
  27k. Swelling Yes      No     Unknown 
  27l. Tiredness/malaise Yes      No     Unknown 
  27m. Watery eyes Yes      No     Unknown 
  27n. Weight loss Yes      No     Unknown 
LATE PRESENTATION 
28. When did you first start having a cough/chest pain/difficulty 
breathing? (circle one) 
<2 wks ago         3-6 mos ago 
2-4 wks ago        6 mos-1 yr ago   
1-3 mos ago       >1 yr ago 
29. What did you think was causing these problems? (write in answer)  
30. Were you seen anywhere else for these problems before coming 
here today? Yes      No     Unknown 
  30a. If yes, where? (circle all that apply) 
Local Clinic 
COSH 







31. Were there any reasons that prevented you from coming to COSH 
earlier? Yes      No     Unknown 
 
 
  31a. If yes, what were those reasons? (write in answer) 
 
32. How much did it cost you to get to COSH today? (write in answer)  
33. How much money does your family get every month? (from all 
sources) (write in answer)  
34. How many people live in your household?    
35. Did any of the following prevent you from coming earlier? (circle one) 
  35a. You were too sick Yes      No     Unknown 
  35b. You had no money for transportation Yes      No     Unknown 
  35c. You had responsibilities at home (taking care of sick relatives, 
etc) Yes      No     Unknown 
  35d. You feel that doctors have been rude or mean to you in the past Yes      No     Unknown 
  35e. You were working Yes      No     Unknown 
  35f. You were afraid you would lose your job if you were diagnosed Yes      No     Unknown 
  35g. You knew other people who had TB, and were worried about 
being diagnosed with TB Yes      No     Unknown 
  35h. You knew other people who had TB, and were worried that it 
meant you had HIV Yes      No     Unknown 
36. Who do you usually consult first when you or your family members 
feel ill? (e.g. traditional healer, community elder, etc.?) (write in 
answer) 
 
37. Do you think COSH is the first place people should go when they 
are sick, or only when other treatments haven’t worked and they are 
very sick? (circle one) 
For all illnesses  
Only for severe illnesses 
HIV TESTING and TREATMENT 
38. Was an HIV test offered? (circle one) 
Yes      No 
 
HIV status already known 
     39. If yes, was the HIV test accepted? (circle one) Yes      No     Unknown 
40. What was the HIV test result? (circle one) Negative     Positive    Unknown 
41. Does the patient have oral thrush?   Yes      No     Unknown 
42. Is the patient being treated in the COSH ARV Clinic? Yes      No     Unknown 
43. Is the patient on ARVs? (circle one) Yes      No     Unknown 
Please obtain the following information (#31a-#33) from the patient’s chart, if available:  
         43a. If yes, when did ARVs start? (write as dd/mmm/yy)  
44. Most recent CD4 count (write in answer)  








MODS Tuberculosis Diagnostics Study 
ARV Clinic Interview Form 
Instructions: Please complete the following information for all MODS patients enrolled from the 
ARV Clinic. Patients who are to see a doctor should also be given the physical examination form 
on page 3. For patients not seeing a doctor, the form can be left blank. 
 
PATIENT DETAILS: 
Why are you here at clinic today? (circle as many as 
apply) 
To see the doctor 
To collect treatment 
For blood draw 
To start ARVs 
Other (specify)______________________ 
 1. Population group (circle one) 
Black     Coloured     Indian     White  
 
Other (specficy)___________ 
 2. Home language (circle one)  Zulu     Xhosa     Sotho     English     Afrikaans       Other (specify)______________ 
TRAVEL AND DISTANCE:  
 3. How did you arrive to the hospital today?  (circle one) Bus     Car     Taxi     Train     Walk 
 4. How long did it take you to come from home to the 
hospital today? (circle one)  <30min     30min-1hr     1hr-2hrs     >2hrs 
 5. What is the name of the nearest clinic to where you 
live? (write in answer)   
DOMESTIC FACILITIES:  
6. What type of water supply do you have in your home? 
(circle one)  
Piped water in home     Communal tap      
Surface water 
7. What type of sanitation do you have at home? (circle 
one) 
Flushing toilet      
VIP (non-flushing outside toilet) 
8. Do you have electricity in your home? (circle one) Yes      No     Unknown     
9. What kind of cooking facilities do you use at home? 
(circle one) Wood     Gas     Paraffin     Electrical stove 
EDUCATION, GRANTS AND INCOME:  
10. Have you ever attended school? (circle one) Yes      No     Unknown 
     10a. If so, what level of education do you have? (circle 
one) Primary     High school     Matric     Tertiary 
11. Are you currently employed?? (circle one) Yes      No     Unknown 
MEDICATION:  
12. Are you taking any medications other than ARVs? (circle one) Yes      No     Unknown 
          12a. Cotrimoxazole (Bactrim)? (show patient pill and circle one) Yes      No     Unknown 
          12b. Fluconozole (Diflucan) (show patient pill and circle one) Yes      No     Unknown 
          12c. Other (please specify-write in answer)  
SYMPTOM HISTORY: 
13. Indicate which of the following symptoms have been experienced by the patient in the last 
month: 
         13a. Rash? (circle one) Yes      No     Unknown 
         13b. Jaundice? (circle one) Yes      No     Unknown 
         13c. Abdominal pains? (circle one) Yes      No     Unknown 
         13d. Nausea/Vomiting? (circle one)  Yes      No     Unknown 
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         13e. Visual changes? (circle one) Yes      No     Unknown 
         13f.  Dizziness? (circle one) Yes      No     Unknown 
         13g. Altered sensation in the extremities? Yes      No     Unknown 
         13h. Vaginal/Penile discharge, itching or burning: Yes      No     Unknown 
         13i.  Are there any days that you wake up where you don’t feel 
happy, or feel depressed? Yes      No     Unknown 
BMI: 
Record patient’s weight in kg (write in number)  
Record patient’s height in cm (write in number)  
FAMILY PLANNING (for all female patients): 
14. Are you using any means of contraception/birth control?  (circle 
one) Yes      No     Unknown 
       14a. If yes, please specify which form of contraception is being 
used? (circle all that apply) 
Oral contraceptives   Condoms 
Tubal ligation            Injectables 
Other (specify):_____________  
15. How many times have you been pregnant (gravidity)? (write in #)  
16. How many children have you given birth to (parity)? (write in #)  
17. When did you last have a PAP smear (did you ever go to the doctor 
to be examined if you have cancer or not)?  (circle one) 
<1year ago         1yr-2yrs ago     
2yrs-3yrs ago     <3yrs ago     
Never had          Unknown 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
